<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BR</journal-id>
<journal-title-group>
<journal-title>Biomedical Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">2049-9434</issn>
<issn pub-type="epub">2049-9442</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/br.2020.1276</article-id>
<article-id pub-id-type="publisher-id">BR-0-0-1276</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Types of acute phase reactants and their importance in vaccination</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Khalil</surname><given-names>Rafaat H.</given-names></name>
<xref rid="af1-br-0-0-1276" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Al-Humadi</surname><given-names>Nabil</given-names></name>
<xref rid="af2-br-0-0-1276" ref-type="aff">2</xref>
<xref rid="c1-br-0-0-1276" ref-type="corresp"/>
</contrib>
</contrib-group>
<aff id="af1-br-0-0-1276"><label>1</label>Department of Biology, College of Science and Technology, Florida Agricultural and Mechanical University, Tallahassee, FL 32307, USA</aff>
<aff id="af2-br-0-0-1276"><label>2</label>Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA</aff>
<author-notes>
<corresp id="c1-br-0-0-1276"><italic>Correspondence to:</italic> Dr Nabil Al-Humadi, Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, 10904 New Hampshire Avenue, Silver Spring, MD 20993, USA <email>nabil.alhumadi@fda.hhs.gov</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>04</month>
<year>2020</year></pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>02</month>
<year>2020</year></pub-date>
<volume>12</volume>
<issue>4</issue>
<fpage>143</fpage>
<lpage>152</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>05</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Khalil et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Vaccines are considered to be one of the most cost-effective life-saving interventions in human history. The body&#x0027;s inflammatory response to vaccines has both desired effects (immune response), undesired effects &#x005B;(acute phase reactions (APRs)&#x005D; and trade-offs. Trade-offs are more potent immune responses which may be potentially difficult to separate from potent acute phase reactions. Thus, studying acute phase proteins (APPs) during vaccination may aid our understanding of APRs and homeostatic changes which can result from inflammatory responses. Depending on the severity of the response in humans, these reactions can be classified as major, moderate or minor. In this review, types of APPs and their importance in vaccination will be discussed.</p>
</abstract>
<kwd-group>
<kwd>acute phase reactants</kwd>
<kwd>c-reactive proteins</kwd>
<kwd>inflammation</kwd>
<kwd>vaccine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>1. Introduction</title>
<p>The association between the strength of the acute phase response and vaccination efficacy is of key importance to human and veterinary medicine. Proteins which are expressed in the acute phase are potential biomarkers for the diagnosis of inflammatory disease, for example, acute phase proteins (APPs) are indicators of successful organ transplantation and can be used to predict the ameliorative effect of cancer therapy (<xref rid="b1-br-0-0-1276" ref-type="bibr">1</xref>,<xref rid="b2-br-0-0-1276" ref-type="bibr">2</xref>). APPs are primarily synthesized in hepatocytes. The acute phase response is a spontaneous reaction triggered by disrupted homeostasis resulting from environmental disturbances (<xref rid="b3-br-0-0-1276" ref-type="bibr">3</xref>). Acute phase reactions (APRs) usually stabilize quickly, after recovering from a disruption to homeostasis within a few days to weeks; however, APPs expression levels often remain elevated in long lasting infection and chronic disease states, such as cancer (<xref rid="b4-br-0-0-1276 b5-br-0-0-1276 b6-br-0-0-1276" ref-type="bibr">4-6</xref>).</p>
<p>Classification of acute phase reactions is dependent on the change in APP concentration: A 10-100-fold elevation is considered major; a 2-10-fold elevation is considered moderate; and a less than 2-fold elevation is considered minor (<xref rid="b7-br-0-0-1276" ref-type="bibr">7</xref>). The APPs elevated in a major APR include C-reactive protein (CRP) and serum amyloid (SA); the APPs elevated in a moderate APR include &#x03B1;1-acid glycoprotein (AGP); and the APPs elevated in a minor APR include fibrinogen, haptoglobin (Hp) and ceruloplasmin (Cp) (<xref rid="b8-br-0-0-1276" ref-type="bibr">8</xref>).</p>
<p>In response to infection, the liver synthesizes a large quantity of APPs (<xref rid="b8-br-0-0-1276" ref-type="bibr">8</xref>). There are 8 proteins which are overexpressed in APRs denoted as &#x2018;positive&#x2019; APPs, including Hp, SA, fibrinogen, Cp, AGP, &#x03B1;-1 antitrypsin (AAT), lactoferrin (Lf) and CRP. Similarly, there are a number of &#x2018;negative&#x2019; APPs the expression levels of which are reduced, including albumin, transferrin and transthyretin (<xref rid="b8-br-0-0-1276" ref-type="bibr">8</xref>).</p>
<p>The APP is elicited by cytokines, including those functioning as positive and negative growth factors and cytokines with proinflammatory or anti-inflammatory activity. Positive or negative growth factor cytokines involved include: Interleukin (IL)-2; IL-3; IL-4; IL-7; IL-10; IL-11; IL-12; and granulocyte-macrophage colony stimulating factor (<xref rid="b9-br-0-0-1276" ref-type="bibr">9</xref>). Proinflammatory cytokines involved include tumour necrosis factor (TNF)-&#x03B1;/&#x03B2;; IL-1&#x03B1;/&#x03B2;; IL-6; IFN-&#x03B1;/&#x03B3;; IL-8; and macrophage inhibitory protein-1(<xref rid="b6-br-0-0-1276" ref-type="bibr">6</xref>). Cytokines involved in the anti-inflammatory response include: IL-1 receptor antagonists; soluble IL-1 receptors; IL-1 binding protein; and TNF-&#x03B1; binding protein. <xref rid="tI-br-0-0-1276" ref-type="table">Table I</xref> shows acute phase reactants associated, inflammatory cytokines and references.</p>
</sec>
<sec>
<title>2. Inflammation and APPs</title>
<p>The acute inflammatory reaction is an essential immune response required for vaccinations to initiate temporary simulated immunity. The innate response is the first branch of the immune system stimulated by invading pathogens, should they cross the body&#x0027;s anatomical and chemical barriers. The innate immune system is also activated by APP synthesis as these molecules mediate inflammation.</p>
<p>After vaccination, pro-inflammatory cells are activated and produce cytokines which diffuse into the extracellular fluid and circulate in the blood. In response, the liver upregulates the synthesis of APPs, preceding the specific immune reaction within a few hours. Monitoring APP expression levels may be an indicator of efficacy of a vaccine in stimulating the innate immune system and may be a useful biomarker in the future development of vaccines.</p>
</sec>
<sec>
<title>3. Types of APPs</title>
<sec>
<title/>
<sec>
<title>C-reactive protein (CRP)</title>
<p>CRP is a member of the short evolutionarily conserved pentraxin group of plasma proteins, consisting of 5 identical non-glycosylated peptide subunits which link to form a cyclic pentamer structure (<xref rid="b10-br-0-0-1276" ref-type="bibr">10</xref>,<xref rid="b11-br-0-0-1276" ref-type="bibr">11</xref>). CRP is produced as a result of pro-inflammatory cytokine signaling primarily mediated by neutrophils and monocytes. CRP concentration is elevated during infection or inflammation as part of the innate immune response and alteration of CRP plasma concentration is dependent on the rate of CRP synthesis and the severity of infection (<xref rid="b10-br-0-0-1276" ref-type="bibr">10</xref>). The half-life of CRP in plasma is &#x007E;19 h and is cleared by the urinary system (<xref rid="b10-br-0-0-1276" ref-type="bibr">10</xref>,<xref rid="b12-br-0-0-1276" ref-type="bibr">12</xref>) and CRP stimulates immune cells by binding to Fc&#x03B3; receptors (Fc&#x03B3;R) on leukocytes (monocytes, neutrophils and cells of a myeloid lineage) and increases production of IgG, linking the innate and adaptive immune systems (<xref rid="b13-br-0-0-1276" ref-type="bibr">13</xref>). CRP-Fc&#x03B3;R binding also facilitates the anti-inflammatory responses (<xref rid="b14-br-0-0-1276" ref-type="bibr">14</xref>).</p>
<p>It has been proposed that CRP may have value as a diagnostic marker for active inflammation and infection. IL-6, IL-1 and TNF-&#x03B1; trigger hepatocyte mediated synthesis of CRP in response to active infection or inflammation. Subsequently, CRP binding to bacterial polysaccharides in the presence of calcium activates downstream compliment pathways and ultimately results in phagocytosis (<xref rid="b15-br-0-0-1276" ref-type="bibr">15</xref>,<xref rid="b16-br-0-0-1276" ref-type="bibr">16</xref>); however, the primary function of CRP is to recognize foreign pathogens and components of damaged cells through binding to phosphocholine (PC), a terminal head group of the lipoteichoic acid which is a component of the cell walls of certain Gram positive bacteria and a component of the mammalian cell membrane. In normal healthy cells, phosphocholine is not exposed however, when cells are damaged or are dying, CRP is able to bind to the PC present on the cell membrane (<xref rid="b17-br-0-0-1276" ref-type="bibr">17</xref>). In addition, CRP promotes complement fixation, binding to phagocytized cells and triggers the elimination of cells targeted by the inflammatory response pathway (<xref rid="b17-br-0-0-1276 b18-br-0-0-1276 b19-br-0-0-1276" ref-type="bibr">17-19</xref>). There is a direct association between the elevated levels of CRP and the risk of coronary artery and cerebrovascular thrombosis interfering with endothelial nitric oxide (NO) bioavailability, by decreasing endothelial NO synthase expression and increasing the production of reactive oxygen species (<xref rid="b20-br-0-0-1276" ref-type="bibr">20</xref>,<xref rid="b21-br-0-0-1276" ref-type="bibr">21</xref>).</p>
<p>In the USA, CRP levels in patients tend to be higher in females compared with males in healthy humans (2.7 vs. 1.6 mg/l, respectively) and these levels are exacerbated with age, for example one study reported CRP levels of 1.4 mg/l between the ages of 20-29 vs. 2.7 mg/l in those over 80(<xref rid="b22-br-0-0-1276" ref-type="bibr">22</xref>). Meanwhile, ethnicity has little effect on CRP levels (<xref rid="b22-br-0-0-1276" ref-type="bibr">22</xref>).</p>
<p>When CRP was studied in non-human species, rabbits served as the primary experimental model due to their susceptibility to infection and the similarity of pathogenesis to what is observed in humans, rabbit CRP behaves more similar to human CRP compared with rat CRP in terms of its dynamic changes during acute phase response (<xref rid="b13-br-0-0-1276" ref-type="bibr">13</xref>,<xref rid="b23-br-0-0-1276" ref-type="bibr">23</xref>).</p>
</sec>
<sec>
<title>Haptoglobin (Hp)</title>
<p>Hp is a glycoprotein synthesized in the liver and present in serum at concentrations of 3-30 &#x00B5;mol/l. Serum levels of Hp increase 3-8-fold in response to inflammation and injury and Hp is eliminated from the plasma in 3-5 days (<xref rid="b24-br-0-0-1276" ref-type="bibr">24</xref>,<xref rid="b25-br-0-0-1276" ref-type="bibr">25</xref>). Hp binds free hemoglobin (Hb) for detoxification and Hb is highly toxic due to its heme group which mediates the generation of hydroxyl radicals (<xref rid="b24-br-0-0-1276" ref-type="bibr">24</xref>). The elimination of Hb and its iron constituent occurs by the formation of a noncovalent Hb-Hp complex which is released into the blood by intravascular hemolysis and subsequently removed by reticuloendothelial receptor-mediated endocytosis and tissue macrophages via interacting with CD163 cell-surface receptor (<xref rid="b26-br-0-0-1276" ref-type="bibr">26</xref>). Free hemoglobin is very toxic to the human body due to its ability to bind NO which is a key modulator of vascular tone (<xref rid="b27-br-0-0-1276" ref-type="bibr">27</xref>). Hp mediated NO binding prevents NO activity in vascular smooth muscle cells resulting in changes to vasomotor constriction, potentially causing endothelial damage which may contribute to cardiovascular disease, and pulmonary and systemic hypertension (<xref rid="b28-br-0-0-1276" ref-type="bibr">28</xref>).</p>
<p>Hp has several functions in the cellular and humoral aspects of the innate and adaptive immune systems (<xref rid="b24-br-0-0-1276" ref-type="bibr">24</xref>), including inhibiting prostaglandin production, enhancing the antibody production, leukocyte recruitment and migration, modulation of cytokine release, which are the regulatory mediators secreted by T cells and other immunoactive cells following an injury, infection and tissue repair (<xref rid="b29-br-0-0-1276 b30-br-0-0-1276 b31-br-0-0-1276" ref-type="bibr">29-31</xref>). Conditions associated with a reduction or absence of Hp, such as hypohaptoglobinemia or ahaptoglobinemia, result in severe allergies involving the skin, lungs and anaphylaxis (<xref rid="b29-br-0-0-1276 b30-br-0-0-1276 b31-br-0-0-1276" ref-type="bibr">29-31</xref>). Hp also suppresses T cell proliferation, including Th2 and Th4 cytokines synthesis (<xref rid="b32-br-0-0-1276" ref-type="bibr">32</xref>), and cyclooxygenase and lipoxygenase activity, thus contributing to the regulation of the immune response to potentially damaging inflammation or infection (<xref rid="b33-br-0-0-1276" ref-type="bibr">33</xref>).</p>
</sec>
<sec>
<title>Serum amyloid A (SAA)</title>
<p>SAA is an APP and a apolipoprotein, which binds to high-density lipoproteins (HDL) in the plasma, During an APR, the fraction of apoA1 in HDL falls while that of SAA rises, becoming the predominant apolipoprotein (apo SAA), exceeding apo A-1 (the major apolipoprotein of native HDL) and reduces the effectiveness of HDL recycling cholesterol to the liver during inflammation (<xref rid="b34-br-0-0-1276" ref-type="bibr">34</xref>). SAA displaces apolipoprotein A-1 from HDL, and becomes the predominant circulating HDL3 apolipoprotein mediating reverse cholesterol transport and inhibiting the LDL oxidation. LDL oxidation promotes foam cell formation, and thus, this reduces the risk of atherosclerosis (<xref rid="b27-br-0-0-1276" ref-type="bibr">27</xref>). SAA is found at concentrations of 40 ug/ml in healthy males in the UK (<xref rid="b34-br-0-0-1276" ref-type="bibr">34</xref>). During acute infection, SAA plasma levels are elevated by up to 1,000-fold (<xref rid="b34-br-0-0-1276" ref-type="bibr">34</xref>). SAA has been shown to be an efficient carrier of retinol during an infection, while retinol is important for promotion and maturation of innate immune cells, expression of retinol transporter is reduced during infection, providing insight into the underlying mechanisms involved in the redirection of retinol in response to infection compensating to the markedly reduced levels of serum retinol binding protein transporter following a microbial infection (<xref rid="b35-br-0-0-1276" ref-type="bibr">35</xref>). During inflammation, macrophages and monocytes present at the inflammatory site release cytokines, such as IL-6, initiating the induction of SAA synthesis and release of SAA by the liver into the plasma (<xref rid="b16-br-0-0-1276" ref-type="bibr">16</xref>).</p>
<p>SAA is a conserved protein which circulates in the plasma and is able to bind to surface ligands of microbial pathogens in a calcium-dependent manner (<xref rid="b36-br-0-0-1276" ref-type="bibr">36</xref>). SAA binds to microbial polysaccharides, which are part of the cell wall of gram-negative bacteria, and matrix components via carbohydrate determinant links, including heparin, 6-phosphorylated mannose, 3-sulfated saccharides and the 4,6-cyclic pyruvate acetal of galactose (<xref rid="b37-br-0-0-1276" ref-type="bibr">37</xref>,<xref rid="b38-br-0-0-1276" ref-type="bibr">38</xref>). SAA binds to apoptotic and necrotic cells facilitating its clearance <italic>in vivo</italic> (<xref rid="b39-br-0-0-1276" ref-type="bibr">39</xref>).</p>
<p>Most species possess two main acute phase apo SAA isoforms of hepatic origin in their serum, SAA1 and SAA2 are APPs with the ability to form amyloid proteins <italic>in vivo</italic> and SAA1 and SAA2 represent multiple allelic forms which are alternatively expressed by three different genes in humans (<xref rid="b40-br-0-0-1276" ref-type="bibr">40</xref>). SAA4 is constitutively expressed across a number of tissues and has been shown to form amyloid when mutated (<xref rid="b41-br-0-0-1276" ref-type="bibr">41</xref>). SAA1a is frequently present in amyloid fibrils and is possibly the most amyloidogenic form of SAA1. Although the majority of SAA1 and SAA2 are found bound to HDL, they are only a minor protein component in a healthy state. This classification helps differentiate between regulated acute phase reactants of hepatic origin or constitutive proteins (<xref rid="b42-br-0-0-1276" ref-type="bibr">42</xref>).</p>
</sec>
<sec>
<title>Fibrinogen</title>
<p>Fibrinogen is an important protein involved in blood clotting, homeostasis, inflammation and tissue repair. Fibrinogen is a 340-kDa soluble glycoprotein found in the blood, and a major component of fibrin which is synthesized in the liver. In healthy adults, fibrinogen plasma levels are &#x007E;150-400 mg/dl, and during infection, expression levels of fibrinogen can increase by &#x2264;20-fold (<xref rid="b43-br-0-0-1276" ref-type="bibr">43</xref>). At a site of injury, fibrinogen facilitates aggregation of activated platelets through binding to glycoprotein IIb/IIIa cell surface receptor (<xref rid="b43-br-0-0-1276" ref-type="bibr">43</xref>), triggering platelet adhesion, and subsequently, thrombin cleaves fibrinogen into fibrin monomers which polymerize to form a clot (<xref rid="b44-br-0-0-1276" ref-type="bibr">44</xref>,<xref rid="b45-br-0-0-1276" ref-type="bibr">45</xref>) and are stabilized by activated factor XIII (<xref rid="b46-br-0-0-1276" ref-type="bibr">46</xref>). The strength of the fibrin clot is influenced by the concentration of fibrinogen (<xref rid="b44-br-0-0-1276" ref-type="bibr">44</xref>). A structural scaffold is formed by the fibrin clot onto which leukocyte platelets and fibroblasts adhere and infiltrate the injury site. Extravascular plasma generates thrombin which ultimately leads to deposition of fibrinogen (<xref rid="b47-br-0-0-1276" ref-type="bibr">47</xref>), therefore injury, infection and auto-immunity are associated with extravascular fibrinogen (<xref rid="b48-br-0-0-1276" ref-type="bibr">48</xref>,<xref rid="b49-br-0-0-1276" ref-type="bibr">49</xref>).</p>
</sec>
<sec>
<title>Ceruloplasmin (Cp)</title>
<p>Cp is a major copper transport protein present in the plasma and is produced by the hepatic parenchymal cells (<xref rid="b50-br-0-0-1276" ref-type="bibr">50</xref>). Human Cp (hCp) is a 132 kDa &#x03B1;2-globulin which can bind up to six copper ions, and serum concentration levels in healthy individuals are &#x007E;0.2-0.6 mg/ml, which increases &#x003E;2-fold during inflammation (<xref rid="b51-br-0-0-1276" ref-type="bibr">51</xref>). Overall, &#x007E;95&#x0025; of serum copper is bound to Cp (<xref rid="b52-br-0-0-1276" ref-type="bibr">52</xref>). hCp has ferroxidase activity and functions in the mobilization of iron for transport by oxidizing Fe<sup>2+</sup> to the less reactive Fe<sup>3+</sup> and incorporating Fe<sup>3+</sup> into apotransferrin (<xref rid="b53-br-0-0-1276" ref-type="bibr">53</xref>). This oxidation prevents the formation of reactive oxygen species and toxic products of iron (<xref rid="b54-br-0-0-1276" ref-type="bibr">54</xref>,<xref rid="b55-br-0-0-1276" ref-type="bibr">55</xref>). Therefore, Cp has an essential role in iron metabolism and the elimination of free iron (<xref rid="b56-br-0-0-1276 b57-br-0-0-1276 b58-br-0-0-1276" ref-type="bibr">56-58</xref>). Cp is an APR and Cp expression levels increase during infection, stress and inflammation (<xref rid="b59-br-0-0-1276" ref-type="bibr">59</xref>). Cp also possesses antioxidant properties and functions in the removal of free radicals such as H<sub>2</sub>O<sub>2</sub> during wound healing, collagen formation and the maturation phase which brings about extracellular matrix remodeling and resolution of the granulation of tissue (<xref rid="b60-br-0-0-1276" ref-type="bibr">60</xref>,<xref rid="b61-br-0-0-1276" ref-type="bibr">61</xref>). However, studies have shown that Cp can also act as a pro-oxidant by promoting the oxidation of low density lipoprotein (<xref rid="b62-br-0-0-1276" ref-type="bibr">62</xref>,<xref rid="b63-br-0-0-1276" ref-type="bibr">63</xref>).</p>
</sec>
<sec>
<title>&#x03B1;1-acid glycoprotein (AGP)</title>
<p>AGP is an APR which stabilizes the biological activity of plasminogen activator inhibitor-1, preventing platelet aggregation (<xref rid="b64-br-0-0-1276" ref-type="bibr">64</xref>), and is present in the plasma of healthy humans at concentrations of 0.6-1.2 mg/ml (<xref rid="b65-br-0-0-1276" ref-type="bibr">65</xref>). However, these expression levels increase 2-7-fold during an APR (<xref rid="b53-br-0-0-1276" ref-type="bibr">53</xref>,<xref rid="b66-br-0-0-1276" ref-type="bibr">66</xref>). AGP expression in the liver is induced by activation of IL-1&#x03B2;, IL-6 and TNF-&#x03B1;, and is inhibited by growth hormone (<xref rid="b67-br-0-0-1276" ref-type="bibr">67</xref>,<xref rid="b68-br-0-0-1276" ref-type="bibr">68</xref>). AGP is considered a natural anti-inflammatory agent with respect to its anti-neutrophilic activity. For example, AGP modulates neutrophil chemotactic migration and superoxide generation in a concentration-dependent manner assisting in the re-establishment of systemic homeostasis following an infection (<xref rid="b59-br-0-0-1276" ref-type="bibr">59</xref>,<xref rid="b69-br-0-0-1276" ref-type="bibr">69</xref>,<xref rid="b70-br-0-0-1276" ref-type="bibr">70</xref>). AGP also inhibits monocyte chemotaxis and cellular leakage caused by histamine and bradykinin levels which are reduced by AGP, and additionally, AGP reduced the synthesis of soluble TNF&#x03B1; receptor leading to an inhibition of the inflammatory process (<xref rid="b70-br-0-0-1276" ref-type="bibr">70</xref>). Meanwhile, AGP induces IL-1 receptor antagonism expressed on peripheral blood monocytes (<xref rid="b71-br-0-0-1276 b72-br-0-0-1276 b73-br-0-0-1276" ref-type="bibr">71-73</xref>).</p>
</sec>
<sec>
<title>&#x03B1;-1 antitrypsin (AAT)</title>
<p>AAT is the most abundant serine protease inhibitor in human blood (<xref rid="b65-br-0-0-1276" ref-type="bibr">65</xref>). AAT is present in bodily fluids, including the saliva, tears, urine, bile and circulating blood. AAT consists of a single polypeptide chain made of 394 amino acid residues containing one free cysteine residue and three asparagine-linked carbohydrate side-chains. AAT aids in the elimination of acute inflammation, tissue proteolytic damage by neutrophil elastase in the lungs and inhibits lipopolysaccharides and the release of inflammatory mediators such as TNF-&#x03B1; and IL-1&#x03B2; (<xref rid="b65-br-0-0-1276" ref-type="bibr">65</xref>,<xref rid="b74-br-0-0-1276" ref-type="bibr">74</xref>,<xref rid="b75-br-0-0-1276" ref-type="bibr">75</xref>). AAT is synthesized in the liver but is also produced by other blood cells such as monocytes, macrophages, pulmonary alveolar cells and by intestinal and corneal epithelium (<xref rid="b65-br-0-0-1276" ref-type="bibr">65</xref>,<xref rid="b74-br-0-0-1276" ref-type="bibr">74</xref>,<xref rid="b75-br-0-0-1276" ref-type="bibr">75</xref>). Synthesis of AAT occurs at a rate of 34 mg/kg and the protein clearance rate (half-life) is 3-5 days. As a result, high plasma concentrations of AAT usually range from 0.9-2 mg/ml in healthy individuals (<xref rid="b76-br-0-0-1276 b77-br-0-0-1276 b78-br-0-0-1276 b79-br-0-0-1276 b80-br-0-0-1276" ref-type="bibr">76-80</xref>). During an inflammatory response, local AAT synthesis results in the invasion of inflammatory cells followed by an acute rise in AAT expression levels by as much as 11-fold (<xref rid="b81-br-0-0-1276" ref-type="bibr">81</xref>).</p>
</sec>
<sec>
<title>Lactoferrin (Lf)</title>
<p>Lf is a multifunctional 80 kDa glycoprotein which binds to Fe3<sup>+</sup> and an innate immunity factor present in a range of secretory fluids, including mammalian exocrine breast milk, saliva, tears and mucosal secretions (<xref rid="b82-br-0-0-1276" ref-type="bibr">82</xref>). Lf is also present in mucosal surfaces and specific leukocyte granules and it can be found in feces following release from fecal leukocytes (<xref rid="b83-br-0-0-1276" ref-type="bibr">83</xref>). Abundant antimicrobial peptides and APPs are present in airway surface liquid. Lf is a bacteriostatic protein which chelates iron from Fe3<sup>+</sup> (<xref rid="b82-br-0-0-1276" ref-type="bibr">82</xref>). Iron is required for bacterial cell division and for the development of biofilms, which are distinct, matrix-encased communities of bacteria, and the biofilm is protects against host defense mechanisms and antibiotics (<xref rid="b84-br-0-0-1276" ref-type="bibr">84</xref>). LF chelation of iron occurs at a higher affinity in an acidic medium (<xref rid="b85-br-0-0-1276" ref-type="bibr">85</xref>), therefore Lf binding to iron results in the prevention of growth and proliferation of iron dependent bacteria, donating this iron to beneficial bacteria, such as lactic acid bacteria (<italic>Lactobacillales</italic>) serves as a barrier against colonization of pathogenic bacteria on the intestinal surface thus preventing infection (<xref rid="b84-br-0-0-1276" ref-type="bibr">84</xref>). Lf also has several other physiological roles, including stimulation of cell growth and proliferation, differentiation, development of immune competence, antifungal, antibacterial and antiviral activities, antioxidant and anti-inflammatory activity and anti-tumor activity (<xref rid="b82-br-0-0-1276" ref-type="bibr">82</xref>,<xref rid="b85-br-0-0-1276" ref-type="bibr">85</xref>). Recombinant Lf (TLf) produced in the filamentous fungus, <italic>Aspergillus awamori</italic>, possesses the same biological activities as human lactoferrin and has been reported to lower mortality in adults with severe blood poisoning (<xref rid="b86-br-0-0-1276" ref-type="bibr">86</xref>) and to have anticancer activities (<xref rid="b87-br-0-0-1276" ref-type="bibr">87</xref>,<xref rid="b88-br-0-0-1276" ref-type="bibr">88</xref>). TLf and human lactoferrin (hLf) have been reported to display changes in immunogenicity and allergenicity in mice (<xref rid="b89-br-0-0-1276" ref-type="bibr">89</xref>). Alteration of Lf glycosylation in human milk collected at different time points during lactation resulted in changes in bacterial binding to epithelial cells (<xref rid="b89-br-0-0-1276" ref-type="bibr">89</xref>). Thus, hLf from milk and TLf may display different bioactivities. hLF is resistant to gastrointestinal tract digestion and may therefore play an important role in intestinal development during the prenatal period and infancy (<xref rid="b90-br-0-0-1276" ref-type="bibr">90</xref>,<xref rid="b91-br-0-0-1276" ref-type="bibr">91</xref>). More importantly, Lf promotes maturation of dendritic cells and therefore may function as a natural defense in neonates against bacterial invasion (<xref rid="b90-br-0-0-1276" ref-type="bibr">90</xref>) as neonates primarily rely on innate immunity (<xref rid="b92-br-0-0-1276" ref-type="bibr">92</xref>).</p>
</sec>
<sec>
<title>Albumin</title>
<p>Human serum albumin (HSA) is a major plasma protein synthesized by the liver functioning in the transport of several endogenous ligands, including fatty acids, ions, thyroxine, bilirubin; and exogenous ligands as well as drugs, such as warfarin, diazepam, phenytoin, non-estradiol anti-inflammatory drugs and digoxin (<xref rid="b93-br-0-0-1276" ref-type="bibr">93</xref>). Albumin is a member of the family of &#x03B1;-fetoprotein, afamin (also called &#x03B1;-albumin) and vitamin D binding protein (<xref rid="b94-br-0-0-1276" ref-type="bibr">94</xref>,<xref rid="b95-br-0-0-1276" ref-type="bibr">95</xref>) and these proteins tend to be homologous, that is, all members of the albuminoid superfamily of proteins are suitably capable of ligand binding and transport, as they possess highly conserved intron/exon organization (<xref rid="b95-br-0-0-1276" ref-type="bibr">95</xref>). HSA is the key regulator of fluid distribution between somatic regions of the body and body compartment (<xref rid="b96-br-0-0-1276" ref-type="bibr">96</xref>). HSA functions to maintain plasma osmotic pressure and its synthesis is regulated by changes in blood osmotic pressure (<xref rid="b94-br-0-0-1276" ref-type="bibr">94</xref>,<xref rid="b97-br-0-0-1276" ref-type="bibr">97</xref>,<xref rid="b98-br-0-0-1276" ref-type="bibr">98</xref>).</p>
<p>HSA is an important biomarker of inflammation in a number of diseases, including cancer, diabetes, rheumatoid arthritis, ischemia and obesity (<xref rid="b99-br-0-0-1276 b100-br-0-0-1276 b101-br-0-0-1276" ref-type="bibr">99-101</xref>). Low expression levels of HSA may indicate malnutrition and decrease in hemoglobin levels (<xref rid="b99-br-0-0-1276" ref-type="bibr">99</xref>). HSA serves as a valuable cell culture medium and was an additive in the production of pharmaceutical vaccines (<xref rid="b102-br-0-0-1276" ref-type="bibr">102</xref>). HSA has also been used for decades in the management of a range of medical and surgical problems, such as for the treatment of acute hypovolemia (surgical blood loss, trauma, or hemorrhage) due to its effect on osmotic pressure providing an oncotic gradient favoring the entry of water from the interstitial space and thus reversing the movement of leaked fluids back into blood vessels (<xref rid="b103-br-0-0-1276" ref-type="bibr">103</xref>,<xref rid="b104-br-0-0-1276" ref-type="bibr">104</xref>).</p>
</sec>
<sec>
<title>Transferrin (Tf)</title>
<p>Tf is a member of the iron-binding glycoprotein family, including lactoferrin (present in intracellular compartments and secretions, such as milk), melanotransferrin (present on melanoma cells) and ovotransferrin (present in egg white of multiple species), and the metal and coordinating anion sites are well conserved in all vertebrates (<xref rid="b93-br-0-0-1276" ref-type="bibr">93</xref>). Each of these iron-binding glycoproteins features a single iron-binding site and are monomeric proteins 76-81 kDa in weight. Tf consists of two structurally similar lobes, namely, the C- and the N-lobes. Plasma transferrin provides body tissues with iron, whereas the remaining transferrin are produced locally and transport iron to restricted regions, including the testes and brain, as these two sites are relatively inaccessible to proteins in the general circulation due to the presence of highly specialized barriers (<xref rid="b104-br-0-0-1276" ref-type="bibr">104</xref>). Liver hepatocytes are the primary sites of Tf production; however, Tf is also synthesized in other organs to a lesser extent, including the choroid plexus (<xref rid="b105-br-0-0-1276" ref-type="bibr">105</xref>). The primary function of Tf is to transport iron from absorption centers in the duodenum and in white blood cell macrophages to all tissues (<xref rid="b105-br-0-0-1276" ref-type="bibr">105</xref>). Tf also functions as a constituent of the innate immune system where its levels decrease during inflammation. The Tf receptor is a receptor for the IgA1 class of antibodies (<xref rid="b106-br-0-0-1276" ref-type="bibr">106</xref>). Tf serves an important role in the somatic regions where erythropoiesis and active cell division occur (<xref rid="b106-br-0-0-1276" ref-type="bibr">106</xref>). Iron-bound Tf is internalized by cells expressing specific Tf receptors by receptor-mediated endocytosis thus contributing to an environment with low free iron capable of inhibiting bacterial growth and multiplication during infection (<xref rid="b96-br-0-0-1276" ref-type="bibr">96</xref>).</p>
</sec>
<sec>
<title>Transthyretin (TTR)</title>
<p>TTR (previously referred to as prealbumin) is a negative APR synthesized and excreted by the kidneys and gastrointestinal tract with a half-life of 1.9 days and expression levels of TTR decrease significantly during inflammation which promotes an APR (<xref rid="b96-br-0-0-1276" ref-type="bibr">96</xref>,<xref rid="b107-br-0-0-1276" ref-type="bibr">107</xref>). TTR is also synthesized in the choroid plexus and forms a complex molecule with retinol binding protein allowing retinol and thyroxine transport (<xref rid="b107-br-0-0-1276" ref-type="bibr">107</xref>). This process is mediated by pro-inflammatory cytokines, such as IL-6, IL-1a and TNF&#x03B1; (<xref rid="b108-br-0-0-1276" ref-type="bibr">108</xref>). It has been reported that TTR functions as a biomarker for predicting poor short-term outcome and disease severity in patients with burn injuries (<xref rid="b109-br-0-0-1276" ref-type="bibr">109</xref>,<xref rid="b110-br-0-0-1276" ref-type="bibr">110</xref>) or respiratory failure (<xref rid="b111-br-0-0-1276" ref-type="bibr">111</xref>), and was strongly correlated with the score of sequential organ failure assessment, and low levels of TTR were associated with an increase in mortality (<xref rid="b112-br-0-0-1276" ref-type="bibr">112</xref>,<xref rid="b113-br-0-0-1276" ref-type="bibr">113</xref>). Patients with low preoperative TTR levels (&#x003C;0.2 g/l) are prone to increased risk of postoperative infections and need longer mechanical ventilation after heart surgery (<xref rid="b113-br-0-0-1276" ref-type="bibr">113</xref>).</p>
</sec>
</sec>
</sec>
<sec>
<title>4. Vaccines and APP</title>
<p>Upon vaccination and introduction of antigens into the body, macrophages and dendritic cells are stimulated, producing inflammatory cytokines and triggering APP synthesis in hepatocytes, which function nonspecifically as part of the innate immune system detecting pathogens or vaccination components (<xref rid="b114-br-0-0-1276" ref-type="bibr">114</xref>). Vaccines have been shown to cause inflammatory responses which has a direct impact on the maintenance of homeostasis, particularly in the kidney and the liver (<xref rid="b115-br-0-0-1276" ref-type="bibr">115</xref>). Disruption of homeostasis during APR can negatively affect the host (<xref rid="b3-br-0-0-1276" ref-type="bibr">3</xref>,<xref rid="b7-br-0-0-1276" ref-type="bibr">7</xref>,<xref rid="b16-br-0-0-1276" ref-type="bibr">16</xref>), for example, plasma levels of a number of microminerals, including iron, may change as they are taken up by hepatocytes and other cell types (<xref rid="b7-br-0-0-1276" ref-type="bibr">7</xref>). As the APR increases the products of metabolism will also increase (<xref rid="b4-br-0-0-1276" ref-type="bibr">4</xref>). The increase in the plasma proteins during APR affects the concentration of the free form of any drug administered at the time of stress, leading to drug dispersal, and variations in plasma protein concentrations during the acute phase response may result in the plasma levels of available drugs to decrease considerably whereas the total drug concentration (free and bound) will be only slightly affected, and thus the effective dose will be altered due to fluctuations in serum protein levels and decreased serum albumin expression levels (<xref rid="b116-br-0-0-1276" ref-type="bibr">116</xref>,<xref rid="b117-br-0-0-1276" ref-type="bibr">117</xref>). Individual variation in the expression levels of APRs in response to inflammatory stimuli, such as vaccines, has been previously reported in cattle (<xref rid="b118-br-0-0-1276" ref-type="bibr">118</xref>), mice (<xref rid="b119-br-0-0-1276" ref-type="bibr">119</xref>) and humans (<xref rid="b120-br-0-0-1276" ref-type="bibr">120</xref>). This difference may be due to individual differences in inflammatory genes (<xref rid="b120-br-0-0-1276" ref-type="bibr">120</xref>,<xref rid="b121-br-0-0-1276" ref-type="bibr">121</xref>). Obesity can alter vaccination responses in mice, wherein the obesity was associated with decreased antibody production and ultimately reduced the efficacy of an influenza vaccine (<xref rid="b122-br-0-0-1276" ref-type="bibr">122</xref>). Furthermore, decreased influenza-specific antibody levels and B-cell function in response to vaccination has also been linked to obesity in humans (<xref rid="b123-br-0-0-1276" ref-type="bibr">123</xref>). Administration of vaccines containing foreign particles into the body triggers local inflammation due to an immediate change in cytokine production, which triggers the clinical symptoms associated with vaccination. Overall, a reduced response to vaccination is a likely indication of an unregulated inflammatory system which may lead to increased risk of disease as the majority of vaccines protect against infection through induction of a B-cell antibody response (<xref rid="b124-br-0-0-1276" ref-type="bibr">124</xref>).</p>
<p>Pro-inflammatory cytokine IL-6 is an important regulator of inflammation and is one of the primary cytokines which stimulate APP synthesis in hepatocytes (<xref rid="b125-br-0-0-1276 b126-br-0-0-1276 b127-br-0-0-1276" ref-type="bibr">125-127</xref>). IL-6 functions in several processes during inflammation, including chemokine production, development of B-cells and dendritic cells, secretion and maturation of antibodies, T-cell maturation, as well as linking the innate and adaptive immune responses (<xref rid="b128-br-0-0-1276" ref-type="bibr">128</xref>,<xref rid="b129-br-0-0-1276" ref-type="bibr">129</xref>). An acute spike of anti-IL-6 was observed 5 days post vaccination in a small study of yellow fever vaccine, indicating its potential role predict vaccine-induced protection (<xref rid="b130-br-0-0-1276" ref-type="bibr">130</xref>). Kurtz <italic>et al</italic> (<xref rid="b131-br-0-0-1276" ref-type="bibr">131</xref>) studied the protective mechanisms of IL-6 against a <italic>Francisella tularensis</italic> live vaccine administered intradermally or intranasally to IL-6 knockout (KO) and wild type mice. The group reported a decline in SSA and Hp in IL-6 KO mice compared with wild type controls, indicating the importance of IL-6 in protection against infection.</p>
<p>In humans, the efficacy of the influenza vaccination has been invaluable. In one study, CRP expression levels increased by 36&#x0025;, further increasing to 40&#x0025; above baseline at day 3, before returning to the normal levels by day 7 following vaccination (<xref rid="b132-br-0-0-1276" ref-type="bibr">132</xref>). In a study of patients &#x003E;65 years old, CRP plasma concentrations spiked at 2 days post vaccination with influenza and pneumococcal vaccines as well as a combination of the two (<xref rid="b133-br-0-0-1276" ref-type="bibr">133</xref>). Another study investigating the influenza vaccine showed that CRP expression levels post-vaccination were dependent on the dose of vaccine (<xref rid="b134-br-0-0-1276" ref-type="bibr">134</xref>). <xref rid="tII-br-0-0-1276" ref-type="table">Table II</xref> show acute phase reactants associated with vaccines.</p>
</sec>
<sec>
<title>5. Effect of adjuvant systems on APP</title>
<p>Adjuvants are compounds joined with other constituents in vaccine formulations (<xref rid="b135-br-0-0-1276" ref-type="bibr">135</xref>) where multiple immunostimulants are combined with adjuvant systems to enhance antibody production and adaptive immune responses to vaccination (<xref rid="b136-br-0-0-1276" ref-type="bibr">136</xref>). Adjuvant components regulate and improve the specificity of the immune system, thus aiming to optimize the immune response to vaccination (<xref rid="b136-br-0-0-1276" ref-type="bibr">136</xref>). To date, there have been at least six novel adjuvants approved for use as vaccine components in the last 20 years (<xref rid="b135-br-0-0-1276" ref-type="bibr">135</xref>,<xref rid="b136-br-0-0-1276" ref-type="bibr">136</xref>). Adjuvant systems can be useful when strong T cell responses are required to protect against complex pathogens formed of several different types of antigens, chronic infections, or in immunocompromised populations such as the elderly or neonates (<xref rid="b137-br-0-0-1276" ref-type="bibr">137</xref>,<xref rid="b138-br-0-0-1276" ref-type="bibr">138</xref>). A previous study on the effects of adjuvants in rabbits indicated that CRP and fibrinogen expression levels were increased following the administration of adjuvant systems AS01, AS03, AS15 and DTPw (<xref rid="b139-br-0-0-1276" ref-type="bibr">139</xref>). The increase in CRP levels increased 9-26-fold after injection of AS01, AS03, or AS15. Comparable effects have also been shown in humans (<xref rid="b140-br-0-0-1276" ref-type="bibr">140</xref>). However, the use of other adjuvants such as aluminum phosphate and aluminum hydroxide did not affect CRP expression levels in the elderly or in the young following a diphtheria-tetanus-poliomyelitis-typhoid vaccine (<xref rid="b141-br-0-0-1276" ref-type="bibr">141</xref>), influenza vaccine (<xref rid="b142-br-0-0-1276" ref-type="bibr">142</xref>) or yellow fever vaccine (<xref rid="b120-br-0-0-1276" ref-type="bibr">120</xref>,<xref rid="b130-br-0-0-1276" ref-type="bibr">130</xref>). Overall, these studies indicate the efficacy of these adjuvant systems in stimulating the adaptive immune response.</p>
</sec>
<sec>
<title>6. Conclusion</title>
<p>APRs a group of 11 key proteins, eight of which are positive and three are negative proteins. During infection, the liver hepatocytes respond by producing a large number of APRs. Upon vaccination, an acute-phase protein reaction may develop which is a part of the innate immune system. Vaccination has also been demonstrated to cause an inflammatory response, which results in homeostatic changes including changes in renal and liver functions. Changes in APR expression levels in response to an inflammatory stimulus may vary across individuals due to genetic, nutritional, age, or other health-associated factors. The health and nutritional status of the individual may affect the response to a given vaccine due to the inflammatory condition. For example, IL-6 (an in&#xFB02;ammatory key mediator and regulator of the majority of APRs) functions in the acute-phase protein response in the innate and adaptive branches of the immune system. CRP, as a prototypical APP, is synthesized in response to pro-inflammatory cytokine signals and CRP expression levels increase in innate immune responses to infection or to injury. Further investigations into the relationships between vaccination and the effect on CRP and other APRs may help clarify the mechanisms by which beneficial and harmful inflammatory responses affect health and influence the immune response.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>No funding was received.</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>RHK and NAH wrote the manuscript, edited and critically reviewed the manuscript. Both authors read and approved the final version of the manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>This article reflects the views of the authors and should not be construed to represent the FDA&#x0027;s views or policies. Dr Humadi&#x0027;s contributions are an informal communication and represent his own best judgement. These comments do not bind or obligate FDA.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-br-0-0-1276"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deans</surname><given-names>C</given-names></name><name><surname>Wigmore</surname><given-names>SJ</given-names></name></person-group><article-title>Systemic inflammation, cachexia and prognosis in patients with cancer</article-title><source>Curr Opin Clin Nutr Metab Care</source><volume>8</volume><fpage>265</fpage><lpage>269</lpage><year>2005</year><pub-id pub-id-type="pmid">15809528</pub-id><pub-id pub-id-type="doi">10.1097/01.mco.0000165004.93707.88</pub-id></element-citation></ref>
<ref id="b2-br-0-0-1276"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: Implications for longevity</article-title><source>Nutr Rev</source><volume>65 (Suppl)</volume><fpage>S253</fpage><lpage>S259</lpage><year>2007</year><pub-id pub-id-type="pmid">18240558</pub-id><pub-id pub-id-type="doi">10.1111/j.1753-4887.2007.tb00372.x</pub-id></element-citation></ref>
<ref id="b3-br-0-0-1276"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cray</surname><given-names>C</given-names></name><name><surname>Zaias</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>NH</given-names></name></person-group><article-title>Acute phase response in animals: A review</article-title><source>Comp Med</source><volume>59</volume><fpage>517</fpage><lpage>526</lpage><year>2009</year><pub-id pub-id-type="pmid">20034426</pub-id></element-citation></ref>
<ref id="b4-br-0-0-1276"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boosalis</surname><given-names>MG</given-names></name><name><surname>Snowdon</surname><given-names>DA</given-names></name><name><surname>Tully</surname><given-names>CL</given-names></name><name><surname>Gross</surname><given-names>MD</given-names></name></person-group><article-title>Acute phase response and plasma carotenoid concentrations in older women: Findings from the nun study</article-title><source>Nutrition</source><volume>12</volume><fpage>475</fpage><lpage>478</lpage><year>1996</year><pub-id pub-id-type="pmid">8878137</pub-id><pub-id pub-id-type="doi">10.1016/s0899-9007(96)91720-7</pub-id></element-citation></ref>
<ref id="b5-br-0-0-1276"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackiewicz</surname><given-names>A</given-names></name></person-group><article-title>Acute phase proteins and transformed cells</article-title><source>Int Rev Cytol</source><volume>170</volume><fpage>225</fpage><lpage>300</lpage><year>1997</year><pub-id pub-id-type="pmid">9002238</pub-id><pub-id pub-id-type="doi">10.1016/s0074-7696(08)61623-x</pub-id></element-citation></ref>
<ref id="b6-br-0-0-1276"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koj</surname><given-names>A</given-names></name></person-group><article-title>Termination of acute-phase response: Role of some cytokines and anti-inflammatory drugs</article-title><source>Gen Pharmacol</source><volume>31</volume><fpage>9</fpage><lpage>18</lpage><year>1998</year><pub-id pub-id-type="pmid">9595271</pub-id><pub-id pub-id-type="doi">10.1016/s0306-3623(97)00435-7</pub-id></element-citation></ref>
<ref id="b7-br-0-0-1276"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceron</surname><given-names>JJ</given-names></name><name><surname>Eckersall</surname><given-names>PD</given-names></name><name><surname>Martynez-Subiela</surname><given-names>S</given-names></name></person-group><article-title>Acute phase proteins in dogs and cats: Current knowledge and future perspectives</article-title><source>Vet Clin Pathol</source><volume>34</volume><fpage>85</fpage><lpage>99</lpage><year>2005</year><pub-id pub-id-type="pmid">15902658</pub-id><pub-id pub-id-type="doi">10.1111/j.1939-165x.2005.tb00019.x</pub-id></element-citation></ref>
<ref id="b8-br-0-0-1276"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go&#x0301;mez-Laguna</surname><given-names>J</given-names></name><name><surname>Salguero</surname><given-names>FJ</given-names></name><name><surname>Pallare&#x0301;s</surname><given-names>FJ</given-names></name><name><surname>Rodri&#x0301;guez-Go&#x0301;mez</surname><given-names>IM</given-names></name><name><surname>Barranco</surname><given-names>I</given-names></name><name><surname>Carrasco</surname><given-names>L</given-names></name></person-group><comment>Acute phase proteins as biomarkers in animal health and welfare. In: Acute Phase Proteins As Early Non-Specific Biomarkers of Human and Veterinary Diseases. Veas F (ed). InTech, pp259-298, 2011</comment></element-citation></ref>
<ref id="b9-br-0-0-1276"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpe-Timms</surname><given-names>KL</given-names></name><name><surname>Nabli</surname><given-names>H</given-names></name><name><surname>Zimmer</surname><given-names>RL</given-names></name><name><surname>Birt</surname><given-names>JA</given-names></name><name><surname>Davis</surname><given-names>JW</given-names></name></person-group><article-title>Inflammatory cytokines differentially up-regulate human endometrial haptoglobin production in women with endometriosis</article-title><source>Hum Reprod</source><volume>25</volume><fpage>1241</fpage><lpage>1250</lpage><year>2010</year><pub-id pub-id-type="pmid">20176595</pub-id><pub-id pub-id-type="doi">10.1093/humrep/deq032</pub-id></element-citation></ref>
<ref id="b10-br-0-0-1276"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suk</surname><given-names>HJ</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Zee</surname><given-names>RY</given-names></name></person-group><article-title>Relation of polymorphism within the C-reactive protein gene and plasma CRP levels</article-title><source>Atherosclerosis</source><volume>178</volume><fpage>139</fpage><lpage>145</lpage><year>2005</year><pub-id pub-id-type="pmid">15585211</pub-id><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.07.033</pub-id></element-citation></ref>
<ref id="b11-br-0-0-1276"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macleod</surname><given-names>CM</given-names></name><name><surname>Avery</surname><given-names>OT</given-names></name></person-group><article-title>The occurrence during acute infections of a protein not normally present in the blood: II. Isolation and properties of the reactive protein</article-title><source>J Exp Med</source><volume>73</volume><fpage>183</fpage><lpage>190</lpage><year>1941</year><pub-id pub-id-type="pmid">19871072</pub-id><pub-id pub-id-type="doi">10.1084/jem.73.2.191</pub-id></element-citation></ref>
<ref id="b12-br-0-0-1276"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballou</surname><given-names>SP</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name></person-group><article-title>C-reactive protein and the acute phase response</article-title><source>Adv Intern Med</source><volume>37</volume><fpage>313</fpage><lpage>336</lpage><year>1992</year><pub-id pub-id-type="pmid">1558000</pub-id></element-citation></ref>
<ref id="b13-br-0-0-1276"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>HC</given-names></name><name><surname>McCarty</surname><given-names>M</given-names></name></person-group><article-title>The occurrence in the rabbit of an acute phase protein analogous to human C reactive protein</article-title><source>J Exp Med</source><volume>93</volume><fpage>25</fpage><lpage>36</lpage><year>1951</year><pub-id pub-id-type="pmid">14803629</pub-id><pub-id pub-id-type="doi">10.1084/jem.93.1.25</pub-id></element-citation></ref>
<ref id="b14-br-0-0-1276"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mold</surname><given-names>C</given-names></name><name><surname>Rodriguez</surname><given-names>W</given-names></name><name><surname>Rodic-Polic</surname><given-names>B</given-names></name><name><surname>Du Clos</surname><given-names>TW</given-names></name></person-group><article-title>C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R</article-title><source>J Immunol</source><volume>169</volume><fpage>7019</fpage><lpage>7025</lpage><year>2002</year><pub-id pub-id-type="pmid">12471137</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.169.12.7019</pub-id></element-citation></ref>
<ref id="b15-br-0-0-1276"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volanakis</surname><given-names>JE</given-names></name><name><surname>Kaplan</surname><given-names>MH</given-names></name></person-group><article-title>Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide</article-title><source>Proc Soc Exp Biol Med</source><volume>136</volume><fpage>612</fpage><lpage>614</lpage><year>1971</year><pub-id pub-id-type="pmid">4395924</pub-id><pub-id pub-id-type="doi">10.3181/00379727-136-35323</pub-id></element-citation></ref>
<ref id="b16-br-0-0-1276"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabay</surname><given-names>C</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name></person-group><article-title>Acute-phase proteins and other systemic responses to inflammation</article-title><source>N Engl J Med</source><volume>340</volume><fpage>448</fpage><lpage>454</lpage><year>1999</year><pub-id pub-id-type="pmid">9971870</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199902113400607</pub-id></element-citation></ref>
<ref id="b17-br-0-0-1276"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volanakis</surname><given-names>JE</given-names></name></person-group><comment>Acute phase proteins in rheumatic disease. In: Arthritis and allied conditions: A textbook of rheumatology. Koopman WJ (ed). 13 edition. Williams &#x0026; Wilkins, Baltimore, MD, pp505-514, 1997</comment></element-citation></ref>
<ref id="b18-br-0-0-1276"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>AK</given-names></name><name><surname>Chouhan</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Boden</surname><given-names>G</given-names></name></person-group><article-title>Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men</article-title><source>Diabetes</source><volume>48</volume><fpage>1156</fpage><lpage>1161</lpage><year>1999</year><pub-id pub-id-type="pmid">10331423</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.48.5.1156</pub-id></element-citation></ref>
<ref id="b19-br-0-0-1276"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegenga</surname><given-names>ME</given-names></name><name><surname>van der</surname><given-names>Crabben SN</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>de Vos</surname><given-names>AF</given-names></name><name><surname>Tanck</surname><given-names>MW</given-names></name><name><surname>Sauerwein</surname><given-names>HP</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name></person-group><article-title>Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans</article-title><source>Diabetes</source><volume>55</volume><fpage>1807</fpage><lpage>1812</lpage><year>2006</year><pub-id pub-id-type="pmid">16731846</pub-id><pub-id pub-id-type="doi">10.2337/db05-1543</pub-id></element-citation></ref>
<ref id="b20-br-0-0-1276"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Hirschfield</surname><given-names>GM</given-names></name></person-group><article-title>C-reactive protein: A critical update</article-title><source>J Clin Invest</source><volume>111</volume><fpage>1805</fpage><lpage>1812</lpage><year>2003</year><pub-id pub-id-type="pmid">12813013</pub-id><pub-id pub-id-type="doi">10.1172/JCI18921</pub-id></element-citation></ref>
<ref id="b21-br-0-0-1276"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>AR</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name><name><surname>Francis</surname><given-names>CW</given-names></name><name><surname>Looney</surname><given-names>RJ</given-names></name><name><surname>Kolassa</surname><given-names>JE</given-names></name><name><surname>Hall</surname><given-names>WJ</given-names></name><name><surname>Abraham</surname><given-names>GN</given-names></name></person-group><article-title>Response of C-reactive protein and serum amyloid A to influenza A infection in older adults</article-title><source>J Infect Dis</source><volume>183</volume><fpage>995</fpage><lpage>999</lpage><year>2001</year><pub-id pub-id-type="pmid">11237822</pub-id><pub-id pub-id-type="doi">10.1086/319275</pub-id></element-citation></ref>
<ref id="b22-br-0-0-1276"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woloshin</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>LM</given-names></name></person-group><article-title>Distribution of C-reactive protein values in the United States</article-title><source>N Engl J Med</source><volume>352</volume><fpage>1611</fpage><lpage>1613</lpage><year>2005</year><pub-id pub-id-type="pmid">15829550</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200504143521525</pub-id></element-citation></ref>
<ref id="b23-br-0-0-1276"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen-Watson</surname><given-names>B</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name></person-group><article-title>Rabbit CRP response to endotoxin administration: Dose-response relationship and kinetics</article-title><source>Proc Soc Exp Biol Med</source><volume>146</volume><fpage>1132</fpage><lpage>1136</lpage><year>1974</year><pub-id pub-id-type="pmid">4608421</pub-id><pub-id pub-id-type="doi">10.3181/00379727-146-38260</pub-id></element-citation></ref>
<ref id="b24-br-0-0-1276"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langlois</surname><given-names>MR</given-names></name><name><surname>Delanghe</surname><given-names>JR</given-names></name></person-group><article-title>Biological and clinical significance of haptoglobin polymorphism in humans</article-title><source>Clin Chem</source><volume>42</volume><fpage>1589</fpage><lpage>1600</lpage><year>1996</year><pub-id pub-id-type="pmid">8855140</pub-id></element-citation></ref>
<ref id="b25-br-0-0-1276"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowman</surname><given-names>BH</given-names></name><name><surname>Kurosky</surname><given-names>A</given-names></name></person-group><article-title>Haptoglobin: The evolutionary product of duplication, unequal crossing over, and point mutation</article-title><source>Adv Hum Genet</source><volume>12</volume><fpage>189</fpage><lpage>261</lpage><comment>453-184</comment><year>1982</year><pub-id pub-id-type="pmid">6751044</pub-id><pub-id pub-id-type="doi">10.1007/978-1-4615-8315-8_3</pub-id></element-citation></ref>
<ref id="b26-br-0-0-1276"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alayash</surname><given-names>AI</given-names></name></person-group><article-title>Redox biology of blood</article-title><source>Antioxid Redox Signal</source><volume>6</volume><fpage>941</fpage><lpage>943</lpage><year>2004</year><pub-id pub-id-type="pmid">15548891</pub-id><pub-id pub-id-type="doi">10.1089/ars.2004.6.941</pub-id></element-citation></ref>
<ref id="b27-br-0-0-1276"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eklund</surname><given-names>KK</given-names></name><name><surname>Niemi</surname><given-names>K</given-names></name><name><surname>Kovanen</surname><given-names>PT</given-names></name></person-group><article-title>Immune functions of serum amyloid A</article-title><source>Crit Rev Immunol</source><volume>32</volume><fpage>335</fpage><lpage>348</lpage><year>2012</year><pub-id pub-id-type="pmid">23237509</pub-id><pub-id pub-id-type="doi">10.1615/critrevimmunol.v32.i4.40</pub-id></element-citation></ref>
<ref id="b28-br-0-0-1276"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minneci</surname><given-names>PC</given-names></name><name><surname>Deans</surname><given-names>KJ</given-names></name><name><surname>Zhi</surname><given-names>H</given-names></name><name><surname>Yuen</surname><given-names>PS</given-names></name><name><surname>Star</surname><given-names>RA</given-names></name><name><surname>Banks</surname><given-names>SM</given-names></name><name><surname>Schechter</surname><given-names>AN</given-names></name><name><surname>Natanson</surname><given-names>C</given-names></name><name><surname>Gladwin</surname><given-names>MT</given-names></name><name><surname>Solomon</surname><given-names>SB</given-names></name></person-group><article-title>Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin</article-title><source>J Clin Invest</source><volume>115</volume><fpage>3409</fpage><lpage>3417</lpage><year>2005</year><pub-id pub-id-type="pmid">16294219</pub-id><pub-id pub-id-type="doi">10.1172/JCI25040</pub-id></element-citation></ref>
<ref id="b29-br-0-0-1276"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilstad</surname><given-names>CW</given-names></name></person-group><article-title>Anaphylactic transfusion reactions</article-title><source>Curr Opin Hematol</source><volume>10</volume><fpage>419</fpage><lpage>423</lpage><year>2003</year><pub-id pub-id-type="pmid">14564171</pub-id><pub-id pub-id-type="doi">10.1097/00062752-200311000-00004</pub-id></element-citation></ref>
<ref id="b30-br-0-0-1276"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>K</given-names></name><name><surname>Macleod</surname><given-names>D</given-names></name><name><surname>Nihlberg</surname><given-names>K</given-names></name><name><surname>Gurcan</surname><given-names>E</given-names></name><name><surname>Bjermer</surname><given-names>L</given-names></name><name><surname>Marko-Varga</surname><given-names>G</given-names></name><name><surname>Westergren-Thorsson</surname><given-names>G</given-names></name></person-group><article-title>Specific haptoglobin expression in bronchoalveolar lavage during differentiation of circulating fibroblast progenitor cells in mild asthma</article-title><source>J Proteome Res</source><volume>5</volume><fpage>1479</fpage><lpage>1483</lpage><year>2006</year><pub-id pub-id-type="pmid">16739999</pub-id><pub-id pub-id-type="doi">10.1021/pr050462h</pub-id></element-citation></ref>
<ref id="b31-br-0-0-1276"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>E</given-names></name><name><surname>Tadokoro</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Niihara</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>I</given-names></name><name><surname>Isa</surname><given-names>K</given-names></name><name><surname>Moriya</surname><given-names>S</given-names></name><name><surname>Ashida</surname><given-names>T</given-names></name><name><surname>Mitsunaga</surname><given-names>S</given-names></name><etal/></person-group><article-title>Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies</article-title><source>Transfusion</source><volume>42</volume><fpage>766</fpage><lpage>773</lpage><year>2002</year><pub-id pub-id-type="pmid">12147031</pub-id><pub-id pub-id-type="doi">10.1046/j.1537-2995.2002.00117.x</pub-id></element-citation></ref>
<ref id="b32-br-0-0-1276"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arredouani</surname><given-names>M</given-names></name><name><surname>Matthijs</surname><given-names>P</given-names></name><name><surname>Van Hoeyveld</surname><given-names>E</given-names></name><name><surname>Kasran</surname><given-names>A</given-names></name><name><surname>Baumann</surname><given-names>H</given-names></name><name><surname>Ceuppens</surname><given-names>JL</given-names></name><name><surname>Stevens</surname><given-names>E</given-names></name></person-group><article-title>Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release</article-title><source>Immunology</source><volume>108</volume><fpage>144</fpage><lpage>151</lpage><year>2003</year><pub-id pub-id-type="pmid">12562322</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2567.2003.01569.x</pub-id></element-citation></ref>
<ref id="b33-br-0-0-1276"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>SA</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name></person-group><article-title>Dual inhibition of cyclooxygenase and lipoxygenase by human haptoglobin: Its polymorphism and relation to hemoglobin binding</article-title><source>Biochem Biophys Res Commun</source><volume>353</volume><fpage>915</fpage><lpage>920</lpage><year>2007</year><pub-id pub-id-type="pmid">17198677</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.12.092</pub-id></element-citation></ref>
<ref id="b34-br-0-0-1276"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Dash</surname><given-names>AC</given-names></name><name><surname>Markham</surname><given-names>RE</given-names></name><name><surname>Thomas</surname><given-names>HC</given-names></name><name><surname>Williams</surname><given-names>BD</given-names></name><name><surname>Petrie</surname><given-names>A</given-names></name></person-group><article-title>Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum</article-title><source>Clin Exp Immunol</source><volume>32</volume><fpage>119</fpage><lpage>124</lpage><year>1978</year><pub-id pub-id-type="pmid">668189</pub-id></element-citation></ref>
<ref id="b35-br-0-0-1276"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derebe</surname><given-names>MG</given-names></name><name><surname>Zlatkov</surname><given-names>CM</given-names></name><name><surname>Gattu</surname><given-names>S</given-names></name><name><surname>Ruhn</surname><given-names>KA</given-names></name><name><surname>Vaishnava</surname><given-names>S</given-names></name><name><surname>Diehl</surname><given-names>GE</given-names></name><name><surname>MacMillan</surname><given-names>JB</given-names></name><name><surname>Williams</surname><given-names>NS</given-names></name><name><surname>Hooper</surname><given-names>LV</given-names></name></person-group><article-title>Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection</article-title><source>Elife</source><volume>3</volume><issue>e03206</issue><year>2014</year><pub-id pub-id-type="pmid">25073702</pub-id><pub-id pub-id-type="doi">10.7554/eLife.03206</pub-id></element-citation></ref>
<ref id="b36-br-0-0-1276"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottazzi</surname><given-names>B</given-names></name><name><surname>Doni</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>An integrated view of humoral innate immunity: Pentraxins as a paradigm</article-title><source>Annu Rev Immunol</source><volume>28</volume><fpage>157</fpage><lpage>183</lpage><year>2010</year><pub-id pub-id-type="pmid">19968561</pub-id><pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101305</pub-id></element-citation></ref>
<ref id="b37-br-0-0-1276"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hind</surname><given-names>CR</given-names></name><name><surname>Collins</surname><given-names>PM</given-names></name><name><surname>Renn</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>RB</given-names></name><name><surname>Caspi</surname><given-names>D</given-names></name><name><surname>Baltz</surname><given-names>ML</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name></person-group><article-title>Binding specificity of serum amyloid P component for the pyruvate acetal of galactose</article-title><source>J Exp Med</source><volume>159</volume><fpage>1058</fpage><lpage>1069</lpage><year>1984</year><pub-id pub-id-type="pmid">6707579</pub-id><pub-id pub-id-type="doi">10.1084/jem.159.4.1058</pub-id></element-citation></ref>
<ref id="b38-br-0-0-1276"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loveless</surname><given-names>RW</given-names></name><name><surname>Floyd-O&#x0027;Sullivan</surname><given-names>G</given-names></name><name><surname>Raynes</surname><given-names>JG</given-names></name><name><surname>Yuen</surname><given-names>CT</given-names></name><name><surname>Feizi</surname><given-names>T</given-names></name></person-group><article-title>Human serum amyloid P is a multispecific adhesive protein whose ligands include 6-phosphorylated mannose and the 3-sulphated saccharides galactose, N-acetylgalactosamine and glucuronic acid</article-title><source>EMBO J</source><volume>11</volume><fpage>813</fpage><lpage>819</lpage><year>1992</year><pub-id pub-id-type="pmid">1547784</pub-id><pub-id pub-id-type="doi">10.1002/j.1460-2075.1992.tb05118.x</pub-id></element-citation></ref>
<ref id="b39-br-0-0-1276"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Familian</surname><given-names>A</given-names></name><name><surname>Zwart</surname><given-names>B</given-names></name><name><surname>Huisman</surname><given-names>HG</given-names></name><name><surname>Rensink</surname><given-names>I</given-names></name><name><surname>Roem</surname><given-names>D</given-names></name><name><surname>Hordijk</surname><given-names>PL</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name></person-group><article-title>Chromatin-independent binding of serum amyloid P component to apoptotic cells</article-title><source>J Immunol</source><volume>167</volume><fpage>647</fpage><lpage>654</lpage><year>2001</year><pub-id pub-id-type="pmid">11441067</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.167.2.647</pub-id></element-citation></ref>
<ref id="b40-br-0-0-1276"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husby</surname><given-names>G</given-names></name><name><surname>Marhaug</surname><given-names>G</given-names></name><name><surname>Dowton</surname><given-names>B</given-names></name><name><surname>Sletten</surname><given-names>K</given-names></name><name><surname>Sipe</surname><given-names>JD</given-names></name></person-group><article-title>Serum amyloid A (SAA): Biochemistry, genetics and the pathogenesis of AA amyloidosis</article-title><source>Int J Exu Clin Invest</source><volume>1</volume><fpage>119</fpage><lpage>137</lpage><year>1994</year><pub-id pub-id-type="doi">10.3109/13506129409148635</pub-id></element-citation></ref>
<ref id="b41-br-0-0-1276"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>CL</given-names></name><name><surname>Kestler</surname><given-names>D</given-names></name><name><surname>Macy</surname><given-names>SD</given-names></name><name><surname>Williams</surname><given-names>TK</given-names></name><name><surname>Weiss</surname><given-names>DT</given-names></name><name><surname>Solomon</surname><given-names>A</given-names></name></person-group><comment>SAA4-related AA amyloidosis. In: XIth International Symposium on Amyloidosis. CRC Press, Boca Raton, FL, 2008</comment></element-citation></ref>
<ref id="b42-br-0-0-1276"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>N</given-names></name><name><surname>Benditt</surname><given-names>EP</given-names></name></person-group><article-title>Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein</article-title><source>Proc Natl Acad Sci USA</source><volume>77</volume><fpage>6860</fpage><lpage>6864</lpage><year>1980</year><pub-id pub-id-type="pmid">6161374</pub-id><pub-id pub-id-type="doi">10.1073/pnas.77.11.6860</pub-id></element-citation></ref>
<ref id="b43-br-0-0-1276"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>JH</given-names></name><name><surname>Szlam</surname><given-names>F</given-names></name><name><surname>Tanaka</surname><given-names>KA</given-names></name><name><surname>Sniecienski</surname><given-names>RM</given-names></name></person-group><article-title>Fibrinogen and hemostasis: A primary hemostatic target for the management of acquired bleeding</article-title><source>Anesth Analg</source><volume>114</volume><fpage>261</fpage><lpage>274</lpage><year>2012</year><pub-id pub-id-type="pmid">21965371</pub-id><pub-id pub-id-type="doi">10.1213/ANE.0b013e31822e1853</pub-id></element-citation></ref>
<ref id="b44-br-0-0-1276"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennewein</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>N</given-names></name><name><surname>Paulus</surname><given-names>P</given-names></name><name><surname>Ellinghaus</surname><given-names>P</given-names></name><name><surname>Eble</surname><given-names>JA</given-names></name><name><surname>Zacharowski</surname><given-names>K</given-names></name></person-group><article-title>Novel aspects of fibrin(ogen) fragments during inflammation</article-title><source>Mol Med</source><volume>17</volume><fpage>568</fpage><lpage>573</lpage><year>2011</year><pub-id pub-id-type="pmid">21210072</pub-id><pub-id pub-id-type="doi">10.2119/molmed.2010.00146</pub-id></element-citation></ref>
<ref id="b45-br-0-0-1276"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosesson</surname><given-names>MW</given-names></name></person-group><article-title>Fibrinogen and fibrin structure and functions</article-title><source>J Thromb Haemost</source><volume>3</volume><fpage>1894</fpage><lpage>1904</lpage><year>2005</year><pub-id pub-id-type="pmid">16102057</pub-id><pub-id pub-id-type="doi">10.1111/j.1538-7836.2005.01365.x</pub-id></element-citation></ref>
<ref id="b46-br-0-0-1276"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>MA</given-names></name><name><surname>Ostrowski</surname><given-names>SR</given-names></name><name><surname>Windelov</surname><given-names>NA</given-names></name><name><surname>Johansson</surname><given-names>PI</given-names></name></person-group><article-title>Fibrinogen concentrates for bleeding trauma patients: What is the evidence?</article-title><source>Vox Sang</source><volume>101</volume><fpage>185</fpage><lpage>190</lpage><year>2011</year><pub-id pub-id-type="pmid">21535437</pub-id><pub-id pub-id-type="doi">10.1111/j.1423-0410.2011.01478.x</pub-id></element-citation></ref>
<ref id="b47-br-0-0-1276"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furie</surname><given-names>B</given-names></name><name><surname>Furie</surname><given-names>BC</given-names></name></person-group><article-title>The molecular basis of blood coagulation</article-title><source>Cell</source><volume>53</volume><fpage>505</fpage><lpage>518</lpage><year>1988</year><pub-id pub-id-type="pmid">3286010</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(88)90567-3</pub-id></element-citation></ref>
<ref id="b48-br-0-0-1276"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colvin</surname><given-names>RB</given-names></name><name><surname>Johnson</surname><given-names>RA</given-names></name><name><surname>Mihm</surname><given-names>MC Jr</given-names></name><name><surname>Dvorak</surname><given-names>HF</given-names></name></person-group><article-title>Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man</article-title><source>J Exp Med</source><volume>138</volume><fpage>686</fpage><lpage>698</lpage><year>1973</year><pub-id pub-id-type="pmid">4580465</pub-id><pub-id pub-id-type="doi">10.1084/jem.138.3.686</pub-id></element-citation></ref>
<ref id="b49-br-0-0-1276"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labarrere</surname><given-names>CA</given-names></name><name><surname>Nelson</surname><given-names>DR</given-names></name><name><surname>Faulk</surname><given-names>WP</given-names></name></person-group><article-title>Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients</article-title><source>Am J Med</source><volume>105</volume><fpage>207</fpage><lpage>213</lpage><year>1998</year><pub-id pub-id-type="pmid">9753023</pub-id><pub-id pub-id-type="doi">10.1016/s0002-9343(98)00246-0</pub-id></element-citation></ref>
<ref id="b50-br-0-0-1276"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Eaker</surname><given-names>D</given-names></name></person-group><article-title>Identification of the thiol groups in human ceruloplasmin</article-title><source>Eur J Biochem</source><volume>132</volume><fpage>241</fpage><lpage>247</lpage><year>1983</year><pub-id pub-id-type="pmid">6840089</pub-id><pub-id pub-id-type="doi">10.1111/j.1432-1033.1983.tb07354.x</pub-id></element-citation></ref>
<ref id="b51-br-0-0-1276"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>GA</given-names></name></person-group><article-title>Studies on Glycoproteins. I. The carbohydrate portion of human ceruloplasmin</article-title><source>J Biol Chem</source><volume>240</volume><fpage>2019</fpage><lpage>2027</lpage><year>1965</year><pub-id pub-id-type="pmid">14301785</pub-id></element-citation></ref>
<ref id="b52-br-0-0-1276"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>ZL</given-names></name><name><surname>Klomp</surname><given-names>LW</given-names></name><name><surname>Gitlin</surname><given-names>JD</given-names></name></person-group><article-title>Aceruloplasminemia: An inherited neurodegenerative disease with impairment of iron homeostasis</article-title><source>Am J Clin Nutr</source><volume>67 (5 Suppl)</volume><fpage>972S</fpage><lpage>977S</lpage><year>1998</year><pub-id pub-id-type="pmid">9587138</pub-id><pub-id pub-id-type="doi">10.1093/ajcn/67.5.972S</pub-id></element-citation></ref>
<ref id="b53-br-0-0-1276"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>S</given-names></name><name><surname>Buclin</surname><given-names>T</given-names></name><name><surname>Decosterd</surname><given-names>LA</given-names></name><name><surname>Telenti</surname><given-names>A</given-names></name><name><surname>Furrer</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>BL</given-names></name><name><surname>Biollaz</surname><given-names>J</given-names></name><name><surname>Eap</surname><given-names>CB</given-names></name></person-group><article-title>Swiss HIV Cohort Study: Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation</article-title><source>Clin Pharmacol Ther</source><volume>80</volume><fpage>307</fpage><lpage>318</lpage><year>2006</year><pub-id pub-id-type="pmid">17015049</pub-id><pub-id pub-id-type="doi">10.1016/j.clpt.2006.06.006</pub-id></element-citation></ref>
<ref id="b54-br-0-0-1276"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osaki</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Frieden</surname><given-names>E</given-names></name></person-group><article-title>The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum</article-title><source>J Biol Chem</source><volume>241</volume><fpage>2746</fpage><lpage>2751</lpage><year>1966</year><pub-id pub-id-type="pmid">5912351</pub-id></element-citation></ref>
<ref id="b55-br-0-0-1276"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osaki</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Frieden</surname><given-names>E</given-names></name></person-group><article-title>The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I</article-title><source>J Biol Chem</source><volume>246</volume><fpage>3018</fpage><lpage>3023</lpage><year>1971</year><pub-id pub-id-type="pmid">5554305</pub-id></element-citation></ref>
<ref id="b56-br-0-0-1276"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attieh</surname><given-names>ZK</given-names></name><name><surname>Mukhopadhyay</surname><given-names>CK</given-names></name><name><surname>Seshadri</surname><given-names>V</given-names></name><name><surname>Tripoulas</surname><given-names>NA</given-names></name><name><surname>Fox</surname><given-names>PL</given-names></name></person-group><article-title>Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism</article-title><source>J Biol Chem</source><volume>274</volume><fpage>1116</fpage><lpage>1123</lpage><year>1999</year><pub-id pub-id-type="pmid">9873059</pub-id><pub-id pub-id-type="doi">10.1074/jbc.274.2.1116</pub-id></element-citation></ref>
<ref id="b57-br-0-0-1276"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>ZL</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Miyajima</surname><given-names>H</given-names></name><name><surname>Serizawa</surname><given-names>M</given-names></name><name><surname>MacGillivray</surname><given-names>RT</given-names></name><name><surname>Gitlin</surname><given-names>JD</given-names></name></person-group><article-title>Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism</article-title><source>Proc Natl Acad Sci USA</source><volume>92</volume><fpage>2539</fpage><lpage>2543</lpage><year>1995</year><pub-id pub-id-type="pmid">7708681</pub-id><pub-id pub-id-type="doi">10.1073/pnas.92.7.2539</pub-id></element-citation></ref>
<ref id="b58-br-0-0-1276"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahey</surname><given-names>ME</given-names></name><name><surname>Gubler</surname><given-names>CJ</given-names></name><name><surname>Chase</surname><given-names>MS</given-names></name><name><surname>Cartwright</surname><given-names>GE</given-names></name><name><surname>Wintrobe</surname><given-names>MM</given-names></name></person-group><article-title>Studies on copper metabolism. II. Hematologic manifestations of copper deficiency in swine</article-title><source>Blood</source><volume>7</volume><fpage>1053</fpage><lpage>1074</lpage><year>1952</year><pub-id pub-id-type="pmid">12997525</pub-id></element-citation></ref>
<ref id="b59-br-0-0-1276"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochepied</surname><given-names>T</given-names></name><name><surname>Berger</surname><given-names>FG</given-names></name><name><surname>Baumann</surname><given-names>H</given-names></name><name><surname>Libert</surname><given-names>C</given-names></name></person-group><article-title>Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties</article-title><source>Cytokine Growth Factor Rev</source><volume>14</volume><fpage>25</fpage><lpage>34</lpage><year>2003</year><pub-id pub-id-type="pmid">12485617</pub-id><pub-id pub-id-type="doi">10.1016/s1359-6101(02)00054-0</pub-id></element-citation></ref>
<ref id="b60-br-0-0-1276"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giurgea</surname><given-names>N</given-names></name><name><surname>Constantinescu</surname><given-names>MI</given-names></name><name><surname>Stanciu</surname><given-names>R</given-names></name><name><surname>Suciu</surname><given-names>S</given-names></name><name><surname>Muresan</surname><given-names>A</given-names></name></person-group><article-title>Ceruloplasmin-acute-phase reactant or endogenous antioxidant? The case of cardiovascular disease</article-title><source>Med Sci Monit</source><volume>11</volume><fpage>RA48</fpage><lpage>RA51</lpage><year>2005</year><pub-id pub-id-type="pmid">15668644</pub-id></element-citation></ref>
<ref id="b61-br-0-0-1276"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutteridge</surname><given-names>JM</given-names></name></person-group><article-title>Caeruloplasmin: A plasma protein, enzyme, and antioxidant</article-title><source>Ann Clin Biochem</source><volume>15</volume><fpage>293</fpage><lpage>296</lpage><year>1978</year><pub-id pub-id-type="pmid">736489</pub-id><pub-id pub-id-type="doi">10.1177/000456327801500170</pub-id></element-citation></ref>
<ref id="b62-br-0-0-1276"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>CK</given-names></name><name><surname>Ehrenwald</surname><given-names>E</given-names></name><name><surname>Fox</surname><given-names>PL</given-names></name></person-group><article-title>Ceruloplasmin enhances smooth muscle cell- and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism</article-title><source>J Biol Chem</source><volume>271</volume><fpage>14773</fpage><lpage>14778</lpage><year>1996</year><pub-id pub-id-type="pmid">8663020</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.25.14773</pub-id></element-citation></ref>
<ref id="b63-br-0-0-1276"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>CK</given-names></name><name><surname>Mazumder</surname><given-names>B</given-names></name><name><surname>Lindley</surname><given-names>PF</given-names></name><name><surname>Fox</surname><given-names>PL</given-names></name></person-group><article-title>Identification of the prooxidant site of human ceruloplasmin: A model for oxidative damage by copper bound to protein surfaces</article-title><source>Proc Natl Acad Sci USA</source><volume>94</volume><fpage>11546</fpage><lpage>11551</lpage><year>1997</year><pub-id pub-id-type="pmid">9326646</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.21.11546</pub-id></element-citation></ref>
<ref id="b64-br-0-0-1276"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolarczyk</surname><given-names>K</given-names></name><name><surname>Gils</surname><given-names>A</given-names></name><name><surname>Boncela</surname><given-names>J</given-names></name><name><surname>Declerck</surname><given-names>PJ</given-names></name><name><surname>Cierniewski</surname><given-names>CS</given-names></name></person-group><article-title>Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein</article-title><source>Biochemistry</source><volume>44</volume><fpage>12384</fpage><lpage>12390</lpage><year>2005</year><pub-id pub-id-type="pmid">16156651</pub-id><pub-id pub-id-type="doi">10.1021/bi050690p</pub-id></element-citation></ref>
<ref id="b65-br-0-0-1276"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geboes</surname><given-names>K</given-names></name><name><surname>Ray</surname><given-names>MB</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name><name><surname>Callea</surname><given-names>F</given-names></name><name><surname>Desmet</surname><given-names>VJ</given-names></name><name><surname>Vantrappen</surname><given-names>G</given-names></name></person-group><article-title>Morphological identification of alpha-I-antitrypsin in the human small intestine</article-title><source>Histopathology</source><volume>6</volume><fpage>55</fpage><lpage>60</lpage><year>1982</year><pub-id pub-id-type="pmid">7035326</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2559.1982.tb02701.x</pub-id></element-citation></ref>
<ref id="b66-br-0-0-1276"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremer</surname><given-names>JM</given-names></name><name><surname>Wilting</surname><given-names>J</given-names></name><name><surname>Janssen</surname><given-names>LH</given-names></name></person-group><article-title>Drug binding to human alpha-1-acid glycoprotein in health and disease</article-title><source>Pharmacol Rev</source><volume>40</volume><fpage>1</fpage><lpage>47</lpage><year>1988</year><pub-id pub-id-type="pmid">3064105</pub-id></element-citation></ref>
<ref id="b67-br-0-0-1276"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barraud</surname><given-names>B</given-names></name><name><surname>Balavoine</surname><given-names>S</given-names></name><name><surname>Feldmann</surname><given-names>G</given-names></name><name><surname>Lardeux</surname><given-names>B</given-names></name></person-group><article-title>Effects of insulin, dexamethasone and cytokines on alpha 1-acid glycoprotein gene expression in primary cultures of normal rat hepatocytes</article-title><source>Inflammation</source><volume>20</volume><fpage>191</fpage><lpage>202</lpage><year>1996</year><pub-id pub-id-type="pmid">8728021</pub-id><pub-id pub-id-type="doi">10.1007/bf01487405</pub-id></element-citation></ref>
<ref id="b68-br-0-0-1276"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mejdoubi</surname><given-names>N</given-names></name><name><surname>Henriques</surname><given-names>C</given-names></name><name><surname>Bui</surname><given-names>E</given-names></name><name><surname>Durand</surname><given-names>G</given-names></name><name><surname>Lardeux</surname><given-names>B</given-names></name><name><surname>Porquet</surname><given-names>D</given-names></name></person-group><article-title>Growth hormone inhibits rat liver alpha-1-acid glycoprotein gene expression in vivo and in vitro</article-title><source>Hepatology</source><volume>29</volume><fpage>186</fpage><lpage>194</lpage><year>1999</year><pub-id pub-id-type="pmid">9862866</pub-id><pub-id pub-id-type="doi">10.1002/hep.510290113</pub-id></element-citation></ref>
<ref id="b69-br-0-0-1276"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>MJ</given-names></name><name><surname>Gewurz</surname><given-names>H</given-names></name><name><surname>Siegel</surname><given-names>JN</given-names></name></person-group><article-title>Inhibition of neutrophil activation by alpha1-acid glycoprotein</article-title><source>Clin Exp Immunol</source><volume>55</volume><fpage>465</fpage><lpage>472</lpage><year>1984</year><pub-id pub-id-type="pmid">6321072</pub-id></element-citation></ref>
<ref id="b70-br-0-0-1276"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laine</surname><given-names>E</given-names></name><name><surname>Couderc</surname><given-names>R</given-names></name><name><surname>Roch-Arveiller</surname><given-names>M</given-names></name><name><surname>Vasson</surname><given-names>MP</given-names></name><name><surname>Giroud</surname><given-names>JP</given-names></name><name><surname>Raichvarg</surname><given-names>D</given-names></name></person-group><article-title>Modulation of human polymorphonuclear neutrophil functions by alpha 1-acid glycoprotein</article-title><source>Inflammation</source><volume>14</volume><fpage>1</fpage><lpage>9</lpage><year>1990</year><pub-id pub-id-type="pmid">2157658</pub-id><pub-id pub-id-type="doi">10.1007/bf00914025</pub-id></element-citation></ref>
<ref id="b71-br-0-0-1276"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilg</surname><given-names>H</given-names></name><name><surname>Vannier</surname><given-names>E</given-names></name><name><surname>Vachino</surname><given-names>G</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Mier</surname><given-names>JW</given-names></name></person-group><article-title>Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells</article-title><source>J Exp Med</source><volume>178</volume><fpage>1629</fpage><lpage>1636</lpage><year>1993</year><pub-id pub-id-type="pmid">7693853</pub-id><pub-id pub-id-type="doi">10.1084/jem.178.5.1629</pub-id></element-citation></ref>
<ref id="b72-br-0-0-1276"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samak</surname><given-names>R</given-names></name><name><surname>Edelstein</surname><given-names>R</given-names></name><name><surname>Israel</surname><given-names>L</given-names></name></person-group><article-title>Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer</article-title><source>Cancer Immunol Immunother</source><volume>13</volume><fpage>38</fpage><lpage>43</lpage><year>1982</year><pub-id pub-id-type="pmid">6984354</pub-id><pub-id pub-id-type="doi">10.1007/bf00200198</pub-id></element-citation></ref>
<ref id="b73-br-0-0-1276"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muchitsch</surname><given-names>EM</given-names></name><name><surname>Teschner</surname><given-names>W</given-names></name><name><surname>Linnau</surname><given-names>Y</given-names></name><name><surname>Pichler</surname><given-names>L</given-names></name></person-group><article-title>In vivo effect of alpha 1-acid glycoprotein on experimentally enhanced capillary permeability in guinea-pig skin</article-title><source>Arch Int Pharmacodyn Ther</source><volume>331</volume><fpage>313</fpage><lpage>321</lpage><year>1996</year><pub-id pub-id-type="pmid">9125002</pub-id></element-citation></ref>
<ref id="b74-br-0-0-1276"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlmutter</surname><given-names>DH</given-names></name><name><surname>Kay</surname><given-names>RM</given-names></name><name><surname>Cole</surname><given-names>FS</given-names></name><name><surname>Rossing</surname><given-names>TH</given-names></name><name><surname>Van Thiel</surname><given-names>D</given-names></name><name><surname>Colten</surname><given-names>HR</given-names></name></person-group><article-title>The cellular defect in alpha 1-proteinase inhibitor (alpha 1-PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA</article-title><source>Proc Natl Acad Sci USA</source><volume>82</volume><fpage>6918</fpage><lpage>6921</lpage><year>1985</year><pub-id pub-id-type="pmid">3876562</pub-id><pub-id pub-id-type="doi">10.1073/pnas.82.20.6918</pub-id></element-citation></ref>
<ref id="b75-br-0-0-1276"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>MB</given-names></name><name><surname>Geboes</surname><given-names>K</given-names></name><name><surname>Callea</surname><given-names>F</given-names></name><name><surname>Desmet</surname><given-names>VJ</given-names></name></person-group><article-title>Alpha-1-antitrypsin immunoreactivity in gastric carcinoid</article-title><source>Histopathology</source><volume>6</volume><fpage>289</fpage><lpage>297</lpage><year>1982</year><pub-id pub-id-type="pmid">6980174</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2559.1982.tb02723.x</pub-id></element-citation></ref>
<ref id="b76-br-0-0-1276"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>MB</given-names></name><name><surname>Barber</surname><given-names>JC</given-names></name><name><surname>Talamo</surname><given-names>RC</given-names></name><name><surname>Langley</surname><given-names>CE</given-names></name></person-group><article-title>Corneal ulceration and the serum antiproteases. I. Alpha 1-antitrypsin</article-title><source>Invest Ophthalmol</source><volume>12</volume><fpage>759</fpage><lpage>770</lpage><year>1973</year><pub-id pub-id-type="pmid">4361492</pub-id></element-citation></ref>
<ref id="b77-br-0-0-1276"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowanadisai</surname><given-names>W</given-names></name><name><surname>Lonnerdal</surname><given-names>B</given-names></name></person-group><article-title>Alpha(1)-antitrypsin and antichymotrypsin in human milk: Origin, concentrations, and stability</article-title><source>Am J Clin Nutr</source><volume>76</volume><fpage>828</fpage><lpage>833</lpage><year>2002</year><pub-id pub-id-type="pmid">12324297</pub-id><pub-id pub-id-type="doi">10.1093/ajcn/76.4.828</pub-id></element-citation></ref>
<ref id="b78-br-0-0-1276"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CM</given-names></name></person-group><article-title>Comparative proteomic analysis of human whole saliva</article-title><source>Arch Oral Biol</source><volume>49</volume><fpage>951</fpage><lpage>962</lpage><year>2004</year><pub-id pub-id-type="pmid">15485636</pub-id><pub-id pub-id-type="doi">10.1016/j.archoralbio.2004.06.003</pub-id></element-citation></ref>
<ref id="b79-br-0-0-1276"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janciauskiene</surname><given-names>S</given-names></name><name><surname>Toth</surname><given-names>E</given-names></name><name><surname>Sahlin</surname><given-names>S</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name></person-group><article-title>Immunochemical and functional properties of biliary alpha-1-antitrypsin</article-title><source>Scand J Clin Lab Invest</source><volume>56</volume><fpage>597</fpage><lpage>608</lpage><year>1996</year><pub-id pub-id-type="pmid">8981655</pub-id><pub-id pub-id-type="doi">10.3109/00365519609090594</pub-id></element-citation></ref>
<ref id="b80-br-0-0-1276"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poortmans</surname><given-names>J</given-names></name><name><surname>Jeanloz</surname><given-names>RW</given-names></name></person-group><article-title>Quantitative immunological determination of 12 plasma proteins excreted in human urine collected before and after exercise</article-title><source>J Clin Invest</source><volume>47</volume><fpage>386</fpage><lpage>393</lpage><year>1968</year><pub-id pub-id-type="pmid">4170390</pub-id><pub-id pub-id-type="doi">10.1172/JCI105735</pub-id></element-citation></ref>
<ref id="b81-br-0-0-1276"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boskovic</surname><given-names>G</given-names></name><name><surname>Twining</surname><given-names>SS</given-names></name></person-group><article-title>Retinol and retinaldehyde specifically increase alpha1-proteinase inhibitor in the human cornea</article-title><source>Biochem J</source><volume>322</volume><fpage>751</fpage><lpage>756</lpage><year>1997</year><pub-id pub-id-type="pmid">9148745</pub-id><pub-id pub-id-type="doi">10.1042/bj3220751</pub-id></element-citation></ref>
<ref id="b82-br-0-0-1276"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonnerdal</surname><given-names>B</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name></person-group><article-title>Lactoferrin: Molecular structure and biological function</article-title><source>Annu Rev Nutr</source><volume>15</volume><fpage>93</fpage><lpage>110</lpage><year>1995</year><pub-id pub-id-type="pmid">8527233</pub-id><pub-id pub-id-type="doi">10.1146/annurev.nu.15.070195.000521</pub-id></element-citation></ref>
<ref id="b83-br-0-0-1276"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Montoya</surname><given-names>IA</given-names></name><name><surname>Cendon</surname><given-names>TS</given-names></name><name><surname>Arevalo-Gallegos</surname><given-names>S</given-names></name><name><surname>Rascon-Cruz</surname><given-names>Q</given-names></name></person-group><article-title>Lactoferrin a multiple bioactive protein: An overview</article-title><source>Biochim Biophys Acta</source><volume>1820</volume><fpage>226</fpage><lpage>236</lpage><year>2012</year><pub-id pub-id-type="pmid">21726601</pub-id><pub-id pub-id-type="doi">10.1016/j.bbagen.2011.06.018</pub-id></element-citation></ref>
<ref id="b84-br-0-0-1276"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Parsek</surname><given-names>MR</given-names></name><name><surname>Greenberg</surname><given-names>EP</given-names></name><name><surname>Welsh</surname><given-names>MJ</given-names></name></person-group><article-title>A component of innate immunity prevents bacterial biofilm development</article-title><source>Nature</source><volume>417</volume><fpage>552</fpage><lpage>555</lpage><year>2002</year><pub-id pub-id-type="pmid">12037568</pub-id><pub-id pub-id-type="doi">10.1038/417552a</pub-id></element-citation></ref>
<ref id="b85-br-0-0-1276"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>HJ</given-names></name></person-group><article-title>Lactoferrin, a bird&#x0027;s eye view</article-title><source>Biochem Cell Biol</source><volume>90</volume><fpage>233</fpage><lpage>244</lpage><year>2012</year><pub-id pub-id-type="pmid">22540735</pub-id><pub-id pub-id-type="doi">10.1139/o2012-016</pub-id></element-citation></ref>
<ref id="b86-br-0-0-1276"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guntupalli</surname><given-names>K</given-names></name><name><surname>Dean</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>PE</given-names></name><name><surname>Bandi</surname><given-names>V</given-names></name><name><surname>Margolis</surname><given-names>B</given-names></name><name><surname>Rivers</surname><given-names>E</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Lodato</surname><given-names>RF</given-names></name><name><surname>Ismail</surname><given-names>PM</given-names></name><name><surname>Reese</surname><given-names>A</given-names></name><etal/></person-group><article-title>A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis</article-title><source>Crit Care Med</source><volume>41</volume><fpage>706</fpage><lpage>716</lpage><year>2013</year><pub-id pub-id-type="pmid">23425819</pub-id><pub-id pub-id-type="doi">10.1097/CCM.0b013e3182741551</pub-id></element-citation></ref>
<ref id="b87-br-0-0-1276"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Digumarti</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Raman</surname><given-names>G</given-names></name><name><surname>Doval</surname><given-names>DC</given-names></name><name><surname>Advani</surname><given-names>SH</given-names></name><name><surname>Julka</surname><given-names>PK</given-names></name><name><surname>Parikh</surname><given-names>PM</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Madhavan</surname><given-names>J</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer</article-title><source>J Thorac Oncol</source><volume>6</volume><fpage>1098</fpage><lpage>1103</lpage><year>2011</year><pub-id pub-id-type="pmid">21532506</pub-id><pub-id pub-id-type="doi">10.1097/JTO.0b013e3182156250</pub-id></element-citation></ref>
<ref id="b88-br-0-0-1276"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>PM</given-names></name><name><surname>Vaid</surname><given-names>A</given-names></name><name><surname>Advani</surname><given-names>SH</given-names></name><name><surname>Digumarti</surname><given-names>R</given-names></name><name><surname>Madhavan</surname><given-names>J</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Bapna</surname><given-names>A</given-names></name><name><surname>Sekhon</surname><given-names>JS</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Ismail</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy</article-title><source>J Clin Oncol</source><volume>29</volume><fpage>4129</fpage><lpage>4136</lpage><year>2011</year><pub-id pub-id-type="pmid">21969509</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2010.34.4127</pub-id></element-citation></ref>
<ref id="b89-br-0-0-1276"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almond</surname><given-names>RJ</given-names></name><name><surname>Flanagan</surname><given-names>BF</given-names></name><name><surname>Antonopoulos</surname><given-names>A</given-names></name><name><surname>Haslam</surname><given-names>SM</given-names></name><name><surname>Dell</surname><given-names>A</given-names></name><name><surname>Kimber</surname><given-names>I</given-names></name><name><surname>Dearman</surname><given-names>RJ</given-names></name></person-group><article-title>Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: Role of glycosylation</article-title><source>Eur J Immunol</source><volume>43</volume><fpage>170</fpage><lpage>181</lpage><year>2013</year><pub-id pub-id-type="pmid">23012214</pub-id><pub-id pub-id-type="doi">10.1002/eji.201142345</pub-id></element-citation></ref>
<ref id="b90-br-0-0-1276"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonnerdal</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Du</surname><given-names>X</given-names></name></person-group><article-title>Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor and exert bioactivities</article-title><source>J Pediatr Gastroenterol Nutr</source><volume>53</volume><fpage>606</fpage><lpage>614</lpage><year>2011</year><pub-id pub-id-type="pmid">21832946</pub-id><pub-id pub-id-type="doi">10.1097/MPG.0b013e318230a419</pub-id></element-citation></ref>
<ref id="b91-br-0-0-1276"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>LA</given-names></name><name><surname>Lonnerdal</surname><given-names>B</given-names></name></person-group><article-title>Persistence of human milk proteins in the breast-fed infant</article-title><source>Acta Paediatr Scand</source><volume>76</volume><fpage>733</fpage><lpage>740</lpage><year>1987</year><pub-id pub-id-type="pmid">3661174</pub-id><pub-id pub-id-type="doi">10.1111/j.1651-2227.1987.tb10557.x</pub-id></element-citation></ref>
<ref id="b92-br-0-0-1276"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname><given-names>JL</given-names></name><name><surname>Levy</surname><given-names>O</given-names></name></person-group><article-title>Role of innate host defenses in susceptibility to early-onset neonatal sepsis</article-title><source>Clin Perinatol</source><volume>37</volume><fpage>307</fpage><lpage>337</lpage><year>2010</year><pub-id pub-id-type="pmid">20569810</pub-id><pub-id pub-id-type="doi">10.1016/j.clp.2010.04.001</pub-id></element-citation></ref>
<ref id="b93-br-0-0-1276"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>LA</given-names></name></person-group><article-title>Molecular evolution of the transferrin family and associated receptors</article-title><source>Biochim Biophys Acta</source><volume>1820</volume><fpage>244</fpage><lpage>255</lpage><year>2012</year><pub-id pub-id-type="pmid">21693173</pub-id><pub-id pub-id-type="doi">10.1016/j.bbagen.2011.06.002</pub-id></element-citation></ref>
<ref id="b94-br-0-0-1276"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>T Jr</given-names></name></person-group><comment>All about albumin. Biochemistry, Genetics and Medical Applications. Academic Press, Inc., San Diego, CA, 1996</comment></element-citation></ref>
<ref id="b95-br-0-0-1276"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasano</surname><given-names>M</given-names></name><name><surname>Fanali</surname><given-names>G</given-names></name><name><surname>Leboffe</surname><given-names>L</given-names></name><name><surname>Ascenzi</surname><given-names>P</given-names></name></person-group><article-title>Heme binding to albuminoid proteins is the result of recent evolution</article-title><source>IUBMB Life</source><volume>59</volume><fpage>436</fpage><lpage>440</lpage><year>2007</year><pub-id pub-id-type="pmid">17654119</pub-id><pub-id pub-id-type="doi">10.1080/15216540701474523</pub-id></element-citation></ref>
<ref id="b96-br-0-0-1276"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aisen</surname><given-names>P</given-names></name></person-group><article-title>Transferrin receptor 1</article-title><source>Int J Biochem Cell Biol</source><volume>36</volume><fpage>2137</fpage><lpage>2143</lpage><year>2004</year><pub-id pub-id-type="pmid">15313461</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2004.02.007</pub-id></element-citation></ref>
<ref id="b97-br-0-0-1276"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>TW</given-names></name></person-group><article-title>Review article: Albumin as a drug-biological effects of albumin unrelated to oncotic pressure</article-title><source>Aliment Pharmacol Ther</source><volume>16 (Suppl 5)</volume><fpage>S6</fpage><lpage>S11</lpage><year>2002</year><pub-id pub-id-type="pmid">12423448</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2036.16.s5.2.x</pub-id></element-citation></ref>
<ref id="b98-br-0-0-1276"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>CM</given-names></name><name><surname>McClain</surname><given-names>CJ</given-names></name><name><surname>Marsano</surname><given-names>LS</given-names></name></person-group><article-title>Albumin therapy in clinical practice</article-title><source>Nutr Clin Pract</source><volume>20</volume><fpage>314</fpage><lpage>320</lpage><year>2005</year><pub-id pub-id-type="pmid">16207669</pub-id><pub-id pub-id-type="doi">10.1177/0115426505020003314</pub-id></element-citation></ref>
<ref id="b99-br-0-0-1276"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Lis</surname><given-names>CG</given-names></name></person-group><article-title>Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature</article-title><source>Nutr J</source><volume>9</volume><issue>69</issue><year>2010</year><pub-id pub-id-type="pmid">21176210</pub-id><pub-id pub-id-type="doi">10.1186/1475-2891-9-69</pub-id></element-citation></ref>
<ref id="b100-br-0-0-1276"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>M</given-names></name><name><surname>Kasayama</surname><given-names>S</given-names></name></person-group><article-title>Clinical impact of glycated albumin as another glycemic control marker</article-title><source>Endocr J</source><volume>57</volume><fpage>751</fpage><lpage>762</lpage><year>2010</year><pub-id pub-id-type="pmid">20724796</pub-id><pub-id pub-id-type="doi">10.1507/endocrj.k10e-138</pub-id></element-citation></ref>
<ref id="b101-br-0-0-1276"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sbarouni</surname><given-names>E</given-names></name><name><surname>Georgiadou</surname><given-names>P</given-names></name><name><surname>Voudris</surname><given-names>V</given-names></name></person-group><article-title>Ischemia modified albumin changes-review and clinical implications</article-title><source>Clin Chem Lab Med</source><volume>49</volume><fpage>177</fpage><lpage>184</lpage><year>2011</year><pub-id pub-id-type="pmid">21083441</pub-id><pub-id pub-id-type="doi">10.1515/CCLM.2011.037</pub-id></element-citation></ref>
<ref id="b102-br-0-0-1276"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marth</surname><given-names>E</given-names></name><name><surname>Kleinhappl</surname><given-names>B</given-names></name></person-group><article-title>Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination</article-title><source>Vaccine</source><volume>20</volume><fpage>532</fpage><lpage>537</lpage><year>2001</year><pub-id pub-id-type="pmid">11672919</pub-id><pub-id pub-id-type="doi">10.1016/s0264-410x(01)00329-2</pub-id></element-citation></ref>
<ref id="b103-br-0-0-1276"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>GR</given-names></name><name><surname>Navickis</surname><given-names>RJ</given-names></name><name><surname>Wilkes</surname><given-names>MM</given-names></name></person-group><article-title>Albumin administration-what is the evidence of clinical benefit? A systematic review of randomized controlled trials</article-title><source>Eur J Anaesthesiol</source><volume>20</volume><fpage>771</fpage><lpage>793</lpage><year>2003</year><pub-id pub-id-type="pmid">14580047</pub-id><pub-id pub-id-type="doi">10.1017/s0265021503001273</pub-id></element-citation></ref>
<ref id="b104-br-0-0-1276"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderson</surname><given-names>P</given-names></name><name><surname>Bunn</surname><given-names>F</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>WP</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Roberts</surname><given-names>I</given-names></name><name><surname>Schierhout</surname><given-names>G</given-names></name></person-group><article-title>Albumin Reviewers: Human albumin solution for resuscitation and volume expansion in critically ill patients</article-title><source>Cochrane Database Syst Rev</source><volume>2004</volume><issue>CD001208</issue><year>2004</year><pub-id pub-id-type="pmid">15495011</pub-id><pub-id pub-id-type="doi">10.1002/14651858.CD001208.pub2</pub-id></element-citation></ref>
<ref id="b105-br-0-0-1276"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idzerda</surname><given-names>RL</given-names></name><name><surname>Huebers</surname><given-names>H</given-names></name><name><surname>Finch</surname><given-names>CA</given-names></name><name><surname>McKnight</surname><given-names>GS</given-names></name></person-group><article-title>Rat transferrin gene expression: Tissue-specific regulation by iron deficiency</article-title><source>Proc Natl Acad Sci USA</source><volume>83</volume><fpage>3723</fpage><lpage>3727</lpage><year>1986</year><pub-id pub-id-type="pmid">3459151</pub-id><pub-id pub-id-type="doi">10.1073/pnas.83.11.3723</pub-id></element-citation></ref>
<ref id="b106-br-0-0-1276"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macedo</surname><given-names>MF</given-names></name><name><surname>de Sousa</surname><given-names>M</given-names></name></person-group><article-title>Transferrin and the transferrin receptor: Of magic bullets and other concerns</article-title><source>Inflamm Allergy Drug Targets</source><volume>7</volume><fpage>41</fpage><lpage>52</lpage><year>2008</year><pub-id pub-id-type="pmid">18473900</pub-id><pub-id pub-id-type="doi">10.2174/187152808784165162</pub-id></element-citation></ref>
<ref id="b107-br-0-0-1276"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingenbleek</surname><given-names>Y</given-names></name><name><surname>Young</surname><given-names>V</given-names></name></person-group><article-title>Transthyretin (prealbumin) in health and disease: Nutritional implications</article-title><source>Annu Rev Nutr</source><volume>14</volume><fpage>495</fpage><lpage>533</lpage><year>1994</year><pub-id pub-id-type="pmid">7946531</pub-id><pub-id pub-id-type="doi">10.1146/annurev.nu.14.070194.002431</pub-id></element-citation></ref>
<ref id="b108-br-0-0-1276"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballmer</surname><given-names>PE</given-names></name></person-group><article-title>Causes and mechanisms of hypoalbuminaemia</article-title><source>Clin Nutr</source><volume>20</volume><fpage>271</fpage><lpage>273</lpage><year>2001</year><pub-id pub-id-type="pmid">11407876</pub-id><pub-id pub-id-type="doi">10.1054/clnu.2001.0439</pub-id></element-citation></ref>
<ref id="b109-br-0-0-1276"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cynober</surname><given-names>L</given-names></name><name><surname>Prugnaud</surname><given-names>O</given-names></name><name><surname>Lioret</surname><given-names>N</given-names></name><name><surname>Duchemin</surname><given-names>C</given-names></name><name><surname>Saizy</surname><given-names>R</given-names></name><name><surname>Giboudeau</surname><given-names>J</given-names></name></person-group><article-title>Serum transthyretin levels in patients with burn injury</article-title><source>Surgery</source><volume>109</volume><fpage>640</fpage><lpage>644</lpage><year>1991</year><pub-id pub-id-type="pmid">2020909</pub-id></element-citation></ref>
<ref id="b110-br-0-0-1276"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HT</given-names></name><name><surname>Yim</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Hur</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>SW</given-names></name><name><surname>Chun</surname><given-names>W</given-names></name></person-group><article-title>Serum transthyretin level is associated with clinical severity rather than nutrition status in massively burned patients</article-title><source>JPEN J Parenter Enteral Nutr</source><volume>38</volume><fpage>966</fpage><lpage>972</lpage><year>2014</year><pub-id pub-id-type="pmid">23976768</pub-id><pub-id pub-id-type="doi">10.1177/0148607113499588</pub-id></element-citation></ref>
<ref id="b111-br-0-0-1276"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bricon</surname><given-names>T</given-names></name><name><surname>Guidet</surname><given-names>B</given-names></name><name><surname>Coudray-Lucas</surname><given-names>C</given-names></name><name><surname>Staikowsky</surname><given-names>F</given-names></name><name><surname>Gabillet</surname><given-names>JM</given-names></name><name><surname>Offenstadt</surname><given-names>G</given-names></name><name><surname>Giboudeau</surname><given-names>J</given-names></name><name><surname>Cynober</surname><given-names>L</given-names></name></person-group><article-title>Biochemical assessment of nutritional status in patients with chronic obstructive pulmonary disease and acute respiratory failure on admission to an intensive care unit</article-title><source>Clin Nutr</source><volume>13</volume><fpage>98</fpage><lpage>104</lpage><year>1994</year><pub-id pub-id-type="pmid">16843367</pub-id><pub-id pub-id-type="doi">10.1016/0261-5614(94)90067-1</pub-id></element-citation></ref>
<ref id="b112-br-0-0-1276"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germano Borges de Oliveira Nascimento Freitas</surname><given-names>R</given-names></name><name><surname>Negrao Nogueira</surname><given-names>RJ</given-names></name><name><surname>Hessel</surname><given-names>G</given-names></name></person-group><article-title>Protein needs of Critically Ill patients receiving parenteral nutrition</article-title><source>Nutr Hosp</source><volume>32</volume><fpage>250</fpage><lpage>255</lpage><year>2015</year><pub-id pub-id-type="pmid">26262724</pub-id><pub-id pub-id-type="doi">10.3305/nh.2015.32.1.8913</pub-id></element-citation></ref>
<ref id="b113-br-0-0-1276"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>PJ</given-names></name><name><surname>Cassiere</surname><given-names>HA</given-names></name><name><surname>Dellis</surname><given-names>SL</given-names></name><name><surname>Manetta</surname><given-names>F</given-names></name><name><surname>Kohn</surname><given-names>N</given-names></name><name><surname>Hartman</surname><given-names>AR</given-names></name></person-group><article-title>Impact of preoperative prealbumin on outcomes after cardiac surgery</article-title><source>JPEN J Parenter Enteral Nutr</source><volume>39</volume><fpage>870</fpage><lpage>874</lpage><year>2015</year><pub-id pub-id-type="pmid">24898210</pub-id><pub-id pub-id-type="doi">10.1177/0148607114536735</pub-id></element-citation></ref>
<ref id="b114-br-0-0-1276"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsemgeest</surname><given-names>SP</given-names></name><name><surname>Kalsbeek</surname><given-names>HC</given-names></name><name><surname>Wensing</surname><given-names>T</given-names></name><name><surname>Koeman</surname><given-names>JP</given-names></name><name><surname>van Ederen</surname><given-names>AM</given-names></name><name><surname>Gruys</surname><given-names>E</given-names></name></person-group><article-title>Concentrations of serum amyloid-A (SAA) and haptoglobin (HP) as parameters of inflammatory diseases in cattle</article-title><source>Vet Q</source><volume>16</volume><fpage>21</fpage><lpage>23</lpage><year>1994</year><pub-id pub-id-type="pmid">8009814</pub-id><pub-id pub-id-type="doi">10.1080/01652176.1994.9694410</pub-id></element-citation></ref>
<ref id="b115-br-0-0-1276"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>PC</given-names></name><name><surname>Auer</surname><given-names>DE</given-names></name><name><surname>Kramer</surname><given-names>H</given-names></name><name><surname>Barry</surname><given-names>D</given-names></name><name><surname>Ng</surname><given-names>JC</given-names></name></person-group><article-title>Effects of inflammation-associated acute-phase response on hepatic and renal indices in the horse</article-title><source>Aust Vet J</source><volume>76</volume><fpage>187</fpage><lpage>194</lpage><year>1998</year><pub-id pub-id-type="pmid">9578755</pub-id><pub-id pub-id-type="doi">10.1111/j.1751-0813.1998.tb10126.x</pub-id></element-citation></ref>
<ref id="b116-br-0-0-1276"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>PC</given-names></name><name><surname>Ng</surname><given-names>JC</given-names></name><name><surname>Auer</surname><given-names>DE</given-names></name></person-group><article-title>The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses</article-title><source>J Vet Pharmacol Ther</source><volume>19</volume><fpage>475</fpage><lpage>481</lpage><year>1996</year><pub-id pub-id-type="pmid">8971677</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2885.1996.tb00085.x</pub-id></element-citation></ref>
<ref id="b117-br-0-0-1276"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>PC</given-names></name><name><surname>Ng</surname><given-names>JC</given-names></name><name><surname>Auer</surname><given-names>DE</given-names></name></person-group><article-title>The effect of the acute-phase response on in vitro drug metabolism and plasma protein binding in the horse</article-title><source>Vet Res Commun</source><volume>21</volume><fpage>361</fpage><lpage>368</lpage><year>1997</year><pub-id pub-id-type="pmid">9232780</pub-id><pub-id pub-id-type="doi">10.1023/a:1005816422279</pub-id></element-citation></ref>
<ref id="b118-br-0-0-1276"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>S</given-names></name><name><surname>Andersen</surname><given-names>PH</given-names></name><name><surname>Toelboell</surname><given-names>T</given-names></name><name><surname>Heegaard</surname><given-names>PM</given-names></name></person-group><article-title>Dose dependency and individual variability of the lipopolysaccharide-induced bovine acute phase protein response</article-title><source>J Dairy Sci</source><volume>87</volume><fpage>3330</fpage><lpage>3339</lpage><year>2004</year><pub-id pub-id-type="pmid">15377612</pub-id><pub-id pub-id-type="doi">10.3168/jds.S0022-0302(04)73469-4</pub-id></element-citation></ref>
<ref id="b119-br-0-0-1276"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>LM</given-names></name><name><surname>Ribeiro</surname><given-names>OG</given-names></name><name><surname>Siqueira</surname><given-names>M</given-names></name><name><surname>De Franco</surname><given-names>M</given-names></name><name><surname>Starobinas</surname><given-names>N</given-names></name><name><surname>Massa</surname><given-names>S</given-names></name><name><surname>Cabrera</surname><given-names>WH</given-names></name><name><surname>Mouton</surname><given-names>D</given-names></name><name><surname>Seman</surname><given-names>M</given-names></name><name><surname>Iba&#x00F1;ez</surname><given-names>OM</given-names></name></person-group><article-title>Innate resistance to infection by intracellular bacterial pathogens differs in mice selected for maximal or minimal acute inflammatory response</article-title><source>Eur J Immunol</source><volume>28</volume><fpage>2913</fpage><lpage>2920</lpage><year>1998</year><pub-id pub-id-type="pmid">9754578</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199809)28:09&lt;2913::AID-IMMU2913&gt;3.0.CO;2-3</pub-id></element-citation></ref>
<ref id="b120-br-0-0-1276"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verschuur</surname><given-names>M</given-names></name><name><surname>van der</surname><given-names>Beek MT</given-names></name><name><surname>Tak</surname><given-names>HS</given-names></name><name><surname>Visser</surname><given-names>LG</given-names></name><name><surname>de Maat</surname><given-names>MP</given-names></name></person-group><article-title>Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination</article-title><source>Blood Coagul Fibrinolysis</source><volume>15</volume><fpage>399</fpage><lpage>404</lpage><year>2004</year><pub-id pub-id-type="pmid">15205588</pub-id><pub-id pub-id-type="doi">10.1097/01.mbc.0000114444.59147.0a</pub-id></element-citation></ref>
<ref id="b121-br-0-0-1276"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsasser</surname><given-names>TH</given-names></name><name><surname>Blum</surname><given-names>JW</given-names></name><name><surname>Kahl</surname><given-names>S</given-names></name></person-group><article-title>Characterization of calves exhibiting a novel inheritable TNF-alpha hyperresponsiveness to endotoxin: Associations with increased pathophysiological complications</article-title><source>J Appl Physiol (1985)</source><volume>98</volume><fpage>2045</fpage><lpage>2055</lpage><year>2005</year><pub-id pub-id-type="pmid">15661839</pub-id><pub-id pub-id-type="doi">10.1152/japplphysiol.01050.2004</pub-id></element-citation></ref>
<ref id="b122-br-0-0-1276"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HL</given-names></name><name><surname>Shim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Cho</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>HJ</given-names></name><name><surname>Ahn</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Nam</surname><given-names>JH</given-names></name></person-group><article-title>Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine</article-title><source>Hum Vaccin Immunother</source><volume>10</volume><fpage>1181</fpage><lpage>1186</lpage><year>2014</year><pub-id pub-id-type="pmid">24614530</pub-id><pub-id pub-id-type="doi">10.4161/hv.28332</pub-id></element-citation></ref>
<ref id="b123-br-0-0-1276"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frasca</surname><given-names>D</given-names></name><name><surname>Ferracci</surname><given-names>F</given-names></name><name><surname>Diaz</surname><given-names>A</given-names></name><name><surname>Romero</surname><given-names>M</given-names></name><name><surname>Lechner</surname><given-names>S</given-names></name><name><surname>Blomberg</surname><given-names>BB</given-names></name></person-group><article-title>Obesity decreases B cell responses in young and elderly individuals</article-title><source>Obesity (Silver Spring)</source><volume>24</volume><fpage>615</fpage><lpage>625</lpage><year>2016</year><pub-id pub-id-type="pmid">26857091</pub-id><pub-id pub-id-type="doi">10.1002/oby.21383</pub-id></element-citation></ref>
<ref id="b124-br-0-0-1276"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisciandro</surname><given-names>JG</given-names></name><name><surname>van den Biggelaar</surname><given-names>AH</given-names></name></person-group><article-title>Neonatal immune function and inflammatory illnesses in later life: Lessons to be learnt from the developing world?</article-title><source>Clin Exp Allergy</source><volume>40</volume><fpage>1719</fpage><lpage>1731</lpage><year>2010</year><pub-id pub-id-type="pmid">20964742</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2222.2010.03629.x</pub-id></element-citation></ref>
<ref id="b125-br-0-0-1276"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckersall</surname><given-names>PD</given-names></name><name><surname>Lawson</surname><given-names>FP</given-names></name><name><surname>Bence</surname><given-names>L</given-names></name><name><surname>Waterston</surname><given-names>MM</given-names></name><name><surname>Lang</surname><given-names>TL</given-names></name><name><surname>Donachie</surname><given-names>W</given-names></name><name><surname>Fontaine</surname><given-names>MC</given-names></name></person-group><article-title>Acute phase protein response in an experimental model of ovine caseous lymphadenitis</article-title><source>BMC Vet Res</source><volume>3</volume><issue>35</issue><year>2007</year><pub-id pub-id-type="pmid">18093286</pub-id><pub-id pub-id-type="doi">10.1186/1746-6148-3-35</pub-id></element-citation></ref>
<ref id="b126-br-0-0-1276"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>EL-Deeb</surname><given-names>WM</given-names></name><name><surname>El-Bahr</surname><given-names>SM</given-names></name></person-group><article-title>Selected biochemical indicators of equine rhabdomyolysis in Arabian horses: Acute phase proteins and trace elements</article-title><source>Equine Vet Sci</source><volume>34</volume><fpage>484</fpage><lpage>488</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jevs.2013.09.012</pub-id></element-citation></ref>
<ref id="b127-br-0-0-1276"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>EL-Deeb</surname><given-names>WM</given-names></name><name><surname>El-Moslemany</surname><given-names>AM</given-names></name><name><surname>Salem</surname><given-names>MA</given-names></name></person-group><article-title>Cardiac troponin I and immune inflammatory response in horses with strangles</article-title><source>Equine Vet Sci</source><volume>51</volume><fpage>18</fpage><lpage>23</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.jevs.2016.12.003</pub-id></element-citation></ref>
<ref id="b128-br-0-0-1276"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SA</given-names></name></person-group><article-title>Directing transition from innate to acquired immunity: Defining a role for IL-6</article-title><source>J Immunol</source><volume>175</volume><fpage>3463</fpage><lpage>3468</lpage><year>2005</year><pub-id pub-id-type="pmid">16148087</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.175.6.3463</pub-id></element-citation></ref>
<ref id="b129-br-0-0-1276"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chomarat</surname><given-names>P</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Davoust</surname><given-names>J</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name></person-group><article-title>IL-6 switches the differentiation of monocytes from dendritic cells to macrophages</article-title><source>Nat Immunol</source><volume>1</volume><fpage>510</fpage><lpage>514</lpage><year>2000</year><pub-id pub-id-type="pmid">11101873</pub-id><pub-id pub-id-type="doi">10.1038/82763</pub-id></element-citation></ref>
<ref id="b130-br-0-0-1276"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der</surname><given-names>Beek MT</given-names></name><name><surname>Visser</surname><given-names>LG</given-names></name><name><surname>de Maat</surname><given-names>MP</given-names></name></person-group><article-title>Yellow fever vaccination as a model to study the response to stimulation of the inflammation system</article-title><source>Vascul Pharmacol</source><volume>39</volume><fpage>117</fpage><lpage>121</lpage><year>2002</year><pub-id pub-id-type="pmid">12616977</pub-id><pub-id pub-id-type="doi">10.1016/s1537-1891(02)00297-5</pub-id></element-citation></ref>
<ref id="b131-br-0-0-1276"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>SL</given-names></name><name><surname>Foreman</surname><given-names>O</given-names></name><name><surname>Bosio</surname><given-names>CM</given-names></name><name><surname>Anver</surname><given-names>MR</given-names></name><name><surname>Elkins</surname><given-names>KL</given-names></name></person-group><article-title>Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection</article-title><source>Infect Immun</source><volume>81</volume><fpage>585</fpage><lpage>597</lpage><year>2013</year><pub-id pub-id-type="pmid">23230288</pub-id><pub-id pub-id-type="doi">10.1128/IAI.01249-12</pub-id></element-citation></ref>
<ref id="b132-br-0-0-1276"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>MY</given-names></name><name><surname>Hanson</surname><given-names>NQ</given-names></name><name><surname>Straka</surname><given-names>RJ</given-names></name><name><surname>Hoke</surname><given-names>TR</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Peacock</surname><given-names>JM</given-names></name><name><surname>Arends</surname><given-names>VL</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name></person-group><article-title>Effect of influenza vaccine on markers of inflammation and lipid profile</article-title><source>J Lab Clin Med</source><volume>145</volume><fpage>323</fpage><lpage>327</lpage><year>2005</year><pub-id pub-id-type="pmid">15976761</pub-id><pub-id pub-id-type="doi">10.1016/j.lab.2005.03.009</pub-id></element-citation></ref>
<ref id="b133-br-0-0-1276"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posthouwer</surname><given-names>D</given-names></name><name><surname>Voorbij</surname><given-names>HA</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Numans</surname><given-names>ME</given-names></name><name><surname>van der Bom</surname><given-names>JG</given-names></name></person-group><article-title>Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation</article-title><source>Vaccine</source><volume>23</volume><fpage>362</fpage><lpage>365</lpage><year>2004</year><pub-id pub-id-type="pmid">15530681</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.05.035</pub-id></element-citation></ref>
<ref id="b134-br-0-0-1276"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treanor</surname><given-names>JJ</given-names></name><name><surname>Taylor</surname><given-names>DN</given-names></name><name><surname>Tussey</surname><given-names>L</given-names></name><name><surname>Hay</surname><given-names>C</given-names></name><name><surname>Nolan</surname><given-names>C</given-names></name><name><surname>Fitzgerald</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Kavita</surname><given-names>U</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Dark</surname><given-names>I</given-names></name><name><surname>Shaw</surname><given-names>A</given-names></name></person-group><article-title>Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults</article-title><source>Vaccine</source><volume>28</volume><fpage>8268</fpage><lpage>8274</lpage><year>2010</year><pub-id pub-id-type="pmid">20969925</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.10.009</pub-id></element-citation></ref>
<ref id="b135-br-0-0-1276"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Njoroge</surname><given-names>L</given-names></name><name><surname>Khayata</surname><given-names>M</given-names></name><name><surname>Zacharias</surname><given-names>M</given-names></name><name><surname>ElAmm</surname><given-names>C</given-names></name></person-group><article-title>Acute myocarditis following influenza vaccine in a heart transplant patient</article-title><source>J Cardiac Failure</source><volume>24 (Suppl)</volume><fpage>S45</fpage><lpage>S46</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.cardfail.2018.07.131</pub-id></element-citation></ref>
<ref id="b136-br-0-0-1276"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcon</surname><given-names>N</given-names></name><name><surname>Leroux-Roels</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name></person-group><comment>Vaccine adjuvants. In: Understanding Modern Vaccines: Perspectives in Vaccinology: Elsevier, pp89-113, 2011</comment></element-citation></ref>
<ref id="b137-br-0-0-1276"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutwiri</surname><given-names>G</given-names></name><name><surname>Gerdts</surname><given-names>V</given-names></name><name><surname>van Drunen</surname><given-names>Littel-van den Hurk S</given-names></name><name><surname>Auray</surname><given-names>G</given-names></name><name><surname>Eng</surname><given-names>N</given-names></name><name><surname>Garlapati</surname><given-names>S</given-names></name><name><surname>Babiuk</surname><given-names>LA</given-names></name><name><surname>Potter</surname><given-names>A</given-names></name></person-group><article-title>Combination adjuvants: The next generation of adjuvants?</article-title><source>Expert Rev Vaccines</source><volume>10</volume><fpage>95</fpage><lpage>107</lpage><year>2011</year><pub-id pub-id-type="pmid">21162624</pub-id><pub-id pub-id-type="doi">10.1586/erv.10.154</pub-id></element-citation></ref>
<ref id="b138-br-0-0-1276"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Ugozzoli</surname><given-names>M</given-names></name><name><surname>Kazzaz</surname><given-names>J</given-names></name><name><surname>Chesko</surname><given-names>J</given-names></name><name><surname>Soenawan</surname><given-names>E</given-names></name><name><surname>Mannucci</surname><given-names>D</given-names></name><name><surname>Titta</surname><given-names>F</given-names></name><name><surname>Contorni</surname><given-names>M</given-names></name><name><surname>Volpini</surname><given-names>G</given-names></name><name><surname>Del Guidice</surname><given-names>G</given-names></name><name><surname>O&#x0027;Hagan</surname><given-names>DT</given-names></name></person-group><article-title>A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens</article-title><source>Vaccine</source><volume>24</volume><fpage>1680</fpage><lpage>1686</lpage><year>2006</year><pub-id pub-id-type="pmid">16300864</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.09.046</pub-id></element-citation></ref>
<ref id="b139-br-0-0-1276"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroux-Roels</surname><given-names>G</given-names></name></person-group><article-title>Unmet needs in modern vaccinology: Adjuvants to improve the immune response</article-title><source>Vaccine</source><volume>28 (Suppl 3)</volume><fpage>C25</fpage><lpage>C36</lpage><year>2010</year><pub-id pub-id-type="pmid">20713254</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.07.021</pub-id></element-citation></ref>
<ref id="b140-br-0-0-1276"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Destexhe</surname><given-names>E</given-names></name><name><surname>Prinsen</surname><given-names>MK</given-names></name><name><surname>van Sch&#x00F6;ll</surname><given-names>I</given-names></name><name><surname>Kuper</surname><given-names>CF</given-names></name><name><surname>Gar&#x00E7;on</surname><given-names>N</given-names></name><name><surname>Veenstra</surname><given-names>S</given-names></name><name><surname>Segal</surname><given-names>L</given-names></name></person-group><article-title>Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies</article-title><source>J Pharmacol Toxicol Methods</source><volume>68</volume><fpage>367</fpage><lpage>373</lpage><year>2013</year><pub-id pub-id-type="pmid">23624216</pub-id><pub-id pub-id-type="doi">10.1016/j.vascn.2013.04.003</pub-id></element-citation></ref>
<ref id="b141-br-0-0-1276"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El</surname><given-names>Yousfi M</given-names></name><name><surname>Mercier</surname><given-names>S</given-names></name><name><surname>Breuill&#x00E9;</surname><given-names>D</given-names></name><name><surname>Denis</surname><given-names>P</given-names></name><name><surname>Papet</surname><given-names>I</given-names></name><name><surname>Mirand</surname><given-names>PP</given-names></name><name><surname>Obled</surname><given-names>C</given-names></name></person-group><article-title>The inflammatory response to vaccination is altered in the elderly</article-title><source>Mech Ageing Dev</source><volume>126</volume><fpage>874</fpage><lpage>881</lpage><year>2005</year><pub-id pub-id-type="pmid">15876450</pub-id><pub-id pub-id-type="doi">10.1016/j.mad.2005.03.008</pub-id></element-citation></ref>
<ref id="b142-br-0-0-1276"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liuba</surname><given-names>P</given-names></name><name><surname>Aburawi</surname><given-names>EH</given-names></name><name><surname>Pesonen</surname><given-names>E</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Truedsson</surname><given-names>L</given-names></name><name><surname>Yl&#x00E4;-Herttuala</surname><given-names>S</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name></person-group><article-title>Residual adverse changes in arterial endothelial function and LDL oxidation after a mild systemic inflammation induced by influenza vaccination</article-title><source>Ann Med</source><volume>39</volume><fpage>392</fpage><lpage>399</lpage><year>2007</year><pub-id pub-id-type="pmid">17701480</pub-id><pub-id pub-id-type="doi">10.1080/07853890701390111</pub-id></element-citation></ref>
<ref id="b143-br-0-0-1276"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>R</given-names></name><name><surname>Shepard</surname><given-names>LW</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>ZK</given-names></name><name><surname>Ye</surname><given-names>RD</given-names></name></person-group><article-title>Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23</article-title><source>J Immunol</source><volume>177</volume><fpage>4072</fpage><lpage>4079</lpage><year>2006</year><pub-id pub-id-type="pmid">16951371</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.177.6.4072</pub-id></element-citation></ref>
<ref id="b144-br-0-0-1276"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name></person-group><article-title>Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-alpha and iNOS in vascular smooth muscle cells</article-title><source>Mol Med Rep</source><volume>12</volume><fpage>6145</fpage><lpage>6151</lpage><year>2015</year><pub-id pub-id-type="pmid">26238934</pub-id><pub-id pub-id-type="doi">10.3892/mmr.2015.4149</pub-id></element-citation></ref>
<ref id="b145-br-0-0-1276"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzaro</surname><given-names>M</given-names></name><name><surname>Bettegazzi</surname><given-names>B</given-names></name><name><surname>Barbariga</surname><given-names>M</given-names></name><name><surname>Codazzi</surname><given-names>F</given-names></name><name><surname>Zacchetti</surname><given-names>D</given-names></name><name><surname>Alessio</surname><given-names>M</given-names></name></person-group><article-title>Ceruloplasmin potentiates nitric oxide synthase activity and cytokine secretion in activated microglia</article-title><source>J Neuroinflammation</source><volume>11</volume><issue>164</issue><year>2014</year><pub-id pub-id-type="pmid">25224679</pub-id><pub-id pub-id-type="doi">10.1186/s12974-014-0164-9</pub-id></element-citation></ref>
<ref id="b146-br-0-0-1276"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>Cordero E</given-names></name><name><surname>Gonzalez</surname><given-names>MM</given-names></name><name><surname>Aguilar</surname><given-names>LD</given-names></name><name><surname>Orozco</surname><given-names>EH</given-names></name><name><surname>Hernandez Pando</surname><given-names>R</given-names></name></person-group><article-title>Alpha-1-acid glycoprotein, its local production and immunopathological participation in experimental pulmonary tuberculosis</article-title><source>Tuberculosis (Edinb)</source><volume>88</volume><fpage>203</fpage><lpage>211</lpage><year>2008</year><pub-id pub-id-type="pmid">18055265</pub-id><pub-id pub-id-type="doi">10.1016/j.tube.2007.10.004</pub-id></element-citation></ref>
<ref id="b147-br-0-0-1276"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Serres</surname><given-names>F</given-names></name><name><surname>Blanco</surname><given-names>I</given-names></name></person-group><article-title>Role of alpha-1 antitrypsin in human health and disease</article-title><source>J Intern Med</source><volume>276</volume><fpage>311</fpage><lpage>335</lpage><year>2014</year><pub-id pub-id-type="pmid">24661570</pub-id><pub-id pub-id-type="doi">10.1111/joim.12239</pub-id></element-citation></ref>
<ref id="b148-br-0-0-1276"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haversen</surname><given-names>L</given-names></name><name><surname>Ohlsson</surname><given-names>BG</given-names></name><name><surname>Hahn-Zoric</surname><given-names>M</given-names></name><name><surname>Hanson</surname><given-names>LA</given-names></name><name><surname>Mattsby-Baltzer</surname><given-names>I</given-names></name></person-group><article-title>Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B</article-title><source>Cell Immunol</source><volume>220</volume><fpage>83</fpage><lpage>95</lpage><year>2002</year><pub-id pub-id-type="pmid">12657243</pub-id><pub-id pub-id-type="doi">10.1016/s0008-8749(03)00006-6</pub-id></element-citation></ref>
<ref id="b149-br-0-0-1276"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du Clos</surname><given-names>TW</given-names></name></person-group><article-title>Function of C-reactive protein</article-title><source>Ann Med</source><volume>32</volume><fpage>274</fpage><lpage>278</lpage><year>2000</year><pub-id pub-id-type="pmid">10852144</pub-id><pub-id pub-id-type="doi">10.3109/07853890009011772</pub-id></element-citation></ref>
<ref id="b150-br-0-0-1276"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spadaro</surname><given-names>M</given-names></name><name><surname>Montone</surname><given-names>M</given-names></name><name><surname>Arigoni</surname><given-names>M</given-names></name><name><surname>Cantarella</surname><given-names>D</given-names></name><name><surname>Forni</surname><given-names>G</given-names></name><name><surname>Pericle</surname><given-names>F</given-names></name><name><surname>Pascolo</surname><given-names>S</given-names></name><name><surname>Calogero</surname><given-names>RA</given-names></name><name><surname>Cavallo</surname><given-names>F</given-names></name></person-group><article-title>Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4</article-title><source>FASEB J</source><volume>28</volume><fpage>416</fpage><lpage>429</lpage><year>2014</year><pub-id pub-id-type="pmid">24088817</pub-id><pub-id pub-id-type="doi">10.1096/fj.13-229591</pub-id></element-citation></ref>
<ref id="b151-br-0-0-1276"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feelders</surname><given-names>RA</given-names></name><name><surname>Vreugdenhil</surname><given-names>G</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Kuiper-Kramer</surname><given-names>PA</given-names></name><name><surname>van Eijk</surname><given-names>HG</given-names></name><name><surname>Swaak</surname><given-names>AJ</given-names></name></person-group><article-title>Regulation of iron metabolism in the acute-phase response: Interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients</article-title><source>Eur J Clin Invest</source><volume>28</volume><fpage>520</fpage><lpage>527</lpage><year>1998</year><pub-id pub-id-type="pmid">9726030</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2362.1998.00323.x</pub-id></element-citation></ref>
<ref id="b152-br-0-0-1276"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartalena</surname><given-names>L</given-names></name><name><surname>Farsetti</surname><given-names>A</given-names></name><name><surname>Flink</surname><given-names>IL</given-names></name><name><surname>Robbins</surname><given-names>J</given-names></name></person-group><article-title>Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells</article-title><source>Mol Endocrinol</source><volume>6</volume><fpage>935</fpage><lpage>942</lpage><year>1992</year><pub-id pub-id-type="pmid">1323058</pub-id><pub-id pub-id-type="doi">10.1210/mend.6.6.1323058</pub-id></element-citation></ref>
<ref id="b153-br-0-0-1276"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louagie</surname><given-names>H</given-names></name><name><surname>Delanghe</surname><given-names>J</given-names></name><name><surname>Desombere</surname><given-names>I</given-names></name><name><surname>De Buyzere</surname><given-names>M</given-names></name><name><surname>Hauser</surname><given-names>P</given-names></name><name><surname>Leroux-Roels</surname><given-names>G</given-names></name></person-group><article-title>Haptoglobin polymorphism and the immune response after hepatitis B vaccination</article-title><source>Vaccine</source><volume>11</volume><fpage>1188</fpage><lpage>1190</lpage><year>1993</year><pub-id pub-id-type="pmid">8256500</pub-id><pub-id pub-id-type="doi">10.1016/0264-410x(93)90041-u</pub-id></element-citation></ref>
<ref id="b154-br-0-0-1276"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borthwick</surname><given-names>NJ</given-names></name><name><surname>Lane</surname><given-names>T</given-names></name><name><surname>Moyo</surname><given-names>N</given-names></name><name><surname>Crook</surname><given-names>A</given-names></name><name><surname>Shim</surname><given-names>JM</given-names></name><name><surname>Baines</surname><given-names>I</given-names></name><name><surname>Wee</surname><given-names>EG</given-names></name><name><surname>Hawkins</surname><given-names>PN</given-names></name><name><surname>Gillmore</surname><given-names>JD</given-names></name><name><surname>Hanke</surname><given-names>T</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name></person-group><article-title>Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1</article-title><source>PLoS One</source><volume>13</volume><issue>e0197299</issue><year>2018</year><pub-id pub-id-type="pmid">29772028</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0197299</pub-id></element-citation></ref>
<ref id="b155-br-0-0-1276"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creech</surname><given-names>CB</given-names></name><name><surname>Frenck</surname><given-names>RW Jr</given-names></name><name><surname>Sheldon</surname><given-names>EA</given-names></name><name><surname>Seiden</surname><given-names>DJ</given-names></name><name><surname>Kankam</surname><given-names>MK</given-names></name><name><surname>Zito</surname><given-names>ET</given-names></name><name><surname>Girgenti</surname><given-names>D</given-names></name><name><surname>Severs</surname><given-names>JM</given-names></name><name><surname>Immermann</surname><given-names>FW</given-names></name><name><surname>McNeil</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial</article-title><source>Vaccine</source><volume>35</volume><fpage>385</fpage><lpage>394</lpage><year>2017</year><pub-id pub-id-type="pmid">27866765</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.032</pub-id></element-citation></ref>
<ref id="b156-br-0-0-1276"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blom</surname><given-names>M</given-names></name><name><surname>Prag</surname><given-names>JB</given-names></name><name><surname>Norredam</surname><given-names>K</given-names></name></person-group><article-title>Alpha 1-Acid glycoprotein, alpha 1-antitrypsin, and ceruloplasmin in human intestinal helminthiases</article-title><source>Am J Trop Med Hyg</source><volume>28</volume><fpage>76</fpage><lpage>83</lpage><year>1979</year><pub-id pub-id-type="pmid">312026</pub-id><pub-id pub-id-type="doi">10.4269/ajtmh.1979.28.76</pub-id></element-citation></ref>
<ref id="b157-br-0-0-1276"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Haque</surname><given-names>R</given-names></name><name><surname>Mondal</surname><given-names>D</given-names></name><name><surname>Buonomo</surname><given-names>E</given-names></name><name><surname>Nayak</surname><given-names>U</given-names></name><name><surname>Mychaleckyj</surname><given-names>JC</given-names></name><name><surname>Kirkpatrick</surname><given-names>B</given-names></name><name><surname>Colgate</surname><given-names>R</given-names></name><name><surname>Carmolli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Environmental enteropathy, oral vaccine failure and growth faltering in infants in bangladesh</article-title><source>EBioMedicine</source><volume>2</volume><fpage>1759</fpage><lpage>1766</lpage><year>2015</year><pub-id pub-id-type="pmid">26870801</pub-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.09.036</pub-id></element-citation></ref>
<ref id="b158-br-0-0-1276"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>SA</given-names></name><name><surname>Kruzel</surname><given-names>ML</given-names></name><name><surname>Actor</surname><given-names>JK</given-names></name></person-group><article-title>Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis</article-title><source>Int Immunopharmacol</source><volume>5</volume><fpage>591</fpage><lpage>599</lpage><year>2005</year><pub-id pub-id-type="pmid">15683854</pub-id><pub-id pub-id-type="doi">10.1016/j.intimp.2004.11.006</pub-id></element-citation></ref>
<ref id="b159-br-0-0-1276"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carty</surname><given-names>CL</given-names></name><name><surname>Heagerty</surname><given-names>P</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>McClung</surname><given-names>EC</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Lum</surname><given-names>D</given-names></name><name><surname>Boespflug</surname><given-names>E</given-names></name><name><surname>McCloud-Gehring</surname><given-names>C</given-names></name><name><surname>Soleimani</surname><given-names>BR</given-names></name><name><surname>Ranchalis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inflammatory response after influenza vaccination in men with and without carotid artery disease</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>26</volume><fpage>2738</fpage><lpage>2744</lpage><year>2006</year><pub-id pub-id-type="pmid">17023683</pub-id><pub-id pub-id-type="doi">10.1161/01.ATV.0000248534.30057.b5</pub-id></element-citation></ref>
<ref id="b160-br-0-0-1276"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>HH</given-names></name></person-group><article-title>Membranous nephropathy and severe acute kidney injury following influenza vaccination</article-title><source>Saudi J Kidney Dis Transpl</source><volume>26</volume><fpage>1289</fpage><lpage>1293</lpage><year>2015</year><pub-id pub-id-type="pmid">26586075</pub-id><pub-id pub-id-type="doi">10.4103/1319-2442.168676</pub-id></element-citation></ref>
<ref id="b161-br-0-0-1276"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>MP</given-names></name><name><surname>Poolman</surname><given-names>J</given-names></name><name><surname>Stork</surname><given-names>M</given-names></name><name><surname>Tommassen</surname><given-names>JPM</given-names></name><name><surname>Weynants</surname><given-names>V</given-names></name></person-group><comment>Vaccine comprising protein NMB0964 from <italic>Neisseria meningitidis</italic>. US Patent 9,259,461. Filed March 6, 2009; issued August 4, 2011</comment></element-citation></ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="tI-br-0-0-1276" position="float">
<label>Table I</label>
<caption><p>Acute phase reactants, associated inflammatory cytokines and references.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle" colspan="4">A, Positive acute phase reactants</th>
</tr>
<tr>
<th align="left" valign="middle">Author, year</th>
<th align="center" valign="middle">Reactant</th>
<th align="center" valign="middle">Associated cytokines</th>
<th align="center" valign="middle">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Sharpe-Timms <italic>et al</italic>, 2010</td>
<td align="left" valign="middle">Haptoglobin</td>
<td align="left" valign="middle">IL1&#x03B2;, IL-6, IL-8, TNF-&#x03B1;,</td>
<td align="center" valign="middle">(<xref rid="b9-br-0-0-1276" ref-type="bibr">9</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">He <italic>et al</italic>, 2006</td>
<td align="left" valign="middle">Serum amyloid</td>
<td align="left" valign="middle">IL1&#x03B2;, IL-6, IL-8, IL-12, IL-23</td>
<td align="center" valign="middle">(<xref rid="b143-br-0-0-1276" ref-type="bibr">143</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Lu <italic>et al</italic>, 2015</td>
<td align="left" valign="middle">Fibrinogen</td>
<td align="left" valign="middle">IL-6, IL-6, TNF-&#x03B1;, IL-1&#x03B2;, IL-8</td>
<td align="center" valign="middle">(<xref rid="b144-br-0-0-1276" ref-type="bibr">144</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Lazzaro <italic>et al</italic>, 2014</td>
<td align="left" valign="middle">Ceruloplasmin</td>
<td align="left" valign="middle">IL-1&#x03B2;, TNF-&#x03B1;, IFN-l</td>
<td align="center" valign="middle">(<xref rid="b145-br-0-0-1276" ref-type="bibr">145</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Martinez Cordero <italic>et al</italic>, 2008</td>
<td align="left" valign="middle">&#x03B1;-1 acid glycoprotein</td>
<td align="left" valign="middle">TNF-&#x03B1;, IL-1, IL-6</td>
<td align="center" valign="middle">(<xref rid="b146-br-0-0-1276" ref-type="bibr">146</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">de Serres and Blanco, 2014</td>
<td align="left" valign="middle">&#x03B1;-1 antitrypsin</td>
<td align="left" valign="middle">TNF-&#x03B1;, IL-6, IL-1&#x03B2;, IL-8, IL-32</td>
<td align="center" valign="middle">(<xref rid="b147-br-0-0-1276" ref-type="bibr">147</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Haversen <italic>et al</italic>, 2002</td>
<td align="left" valign="middle">Lactoferrin</td>
<td align="left" valign="middle">TNF-&#x03B1;, IL-6, IL-1&#x03B2;, IL-8</td>
<td align="center" valign="middle">(<xref rid="b148-br-0-0-1276" ref-type="bibr">148</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Du Clos, 2000</td>
<td align="left" valign="middle">C-reactive protein</td>
<td align="left" valign="middle">IL-6, IL-1a, IL-1&#x03B2;, TNF-&#x03B1;</td>
<td align="center" valign="middle">(<xref rid="b149-br-0-0-1276" ref-type="bibr">149</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="4">B, Negative acute phase reactants</td>
</tr>
<tr>
<td align="left" valign="middle">Author, year</td>
<td align="center" valign="middle">Reactant</td>
<td align="center" valign="middle">Associated cytokines</td>
<td align="center" valign="middle">(Refs.)</td>
</tr>
<tr>
<td align="left" valign="middle">Spadaro <italic>et al</italic>, 2014</td>
<td align="left" valign="middle">Albumin</td>
<td align="left" valign="middle">IL-6, TNF-&#x03B1;</td>
<td align="center" valign="middle">(<xref rid="b150-br-0-0-1276" ref-type="bibr">150</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Feelders <italic>et al</italic>, 1998</td>
<td align="left" valign="middle">Transferrin</td>
<td align="left" valign="middle">IL-6, TNF-&#x03B1;, IL1</td>
<td align="center" valign="middle">(<xref rid="b151-br-0-0-1276" ref-type="bibr">151</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Bartalena <italic>et al</italic>, 1992</td>
<td align="left" valign="middle">Transthyretin</td>
<td align="left" valign="middle">IL-6, IL-1, TNF-&#x03B1;</td>
<td align="center" valign="middle">(<xref rid="b152-br-0-0-1276" ref-type="bibr">152</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>IL, interleukin; TNF, tumor necrosis factor.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-br-0-0-1276" position="float">
<label>Table II</label>
<caption><p>Acute phase reactants associated with vaccines.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Author, year</th>
<th align="center" valign="middle">Vaccine</th>
<th align="center" valign="middle">Acute phase reactant</th>
<th align="center" valign="middle">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Louagie <italic>et al</italic>, 1993</td>
<td align="left" valign="middle">Hepatitis B</td>
<td align="left" valign="middle">Haptoglobin</td>
<td align="center" valign="middle">(<xref rid="b153-br-0-0-1276" ref-type="bibr">153</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Borthwick <italic>et al</italic>, 2018</td>
<td align="left" valign="middle">Human immunodeficiency virus core DNA</td>
<td align="left" valign="middle">Serum amyloid</td>
<td align="center" valign="middle">(<xref rid="b154-br-0-0-1276" ref-type="bibr">154</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Creech <italic>et al</italic>, 2017</td>
<td align="left" valign="middle"><italic>S. aureus</italic> capsular polysaccharides</td>
<td align="left" valign="middle">Fibrinogen</td>
<td align="center" valign="middle">(<xref rid="b155-br-0-0-1276" ref-type="bibr">155</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Blom <italic>et al</italic>, 1979</td>
<td align="left" valign="middle">Typhoid. AB.-cholera</td>
<td align="left" valign="middle">Ceruloplasmin, &#x03B1;-1 glycoprotein</td>
<td align="center" valign="middle">(<xref rid="b156-br-0-0-1276" ref-type="bibr">156</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Naylor <italic>et al</italic>, 2015</td>
<td align="left" valign="middle">Rotavirus and poliovirus</td>
<td align="left" valign="middle">&#x03B1;-1 antitrypsin</td>
<td align="center" valign="middle">(<xref rid="b157-br-0-0-1276" ref-type="bibr">157</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Hwang <italic>et al</italic>, 2005</td>
<td align="left" valign="middle">Bacillus Calmette-Guerin</td>
<td align="left" valign="middle">Lactoferrin</td>
<td align="center" valign="middle">(<xref rid="b158-br-0-0-1276" ref-type="bibr">158</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Carty <italic>et al</italic>, 2006</td>
<td align="left" valign="middle">Influenza</td>
<td align="left" valign="middle">C-reactive protein, transthyretin</td>
<td align="center" valign="middle">(<xref rid="b159-br-0-0-1276" ref-type="bibr">159</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Patel and Shah, 2015</td>
<td align="left" valign="middle">H1N1 influenza</td>
<td align="left" valign="middle">Albumin</td>
<td align="center" valign="middle">(<xref rid="b160-br-0-0-1276" ref-type="bibr">160</xref>)</td>
</tr>
<tr>
<td align="left" valign="middle">Bos <italic>et al</italic>, 2016</td>
<td align="left" valign="middle"><italic>Neisseria gonorrhoeae</italic></td>
<td align="left" valign="middle">Transferrin</td>
<td align="center" valign="middle">(<xref rid="b161-br-0-0-1276" ref-type="bibr">161</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
